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ABSTRACT 
 Senecavirus A (SVA), formerly known as Seneca Valley Virus, is a single-strand, positive-
sense RNA virus of the family Picornaviridae associated with recent outbreaks of idiopathic 
vesicular disease and increased neonate mortality in several swine producing countries. SVA is 
clinically indistinguishable from foot-and-mouth disease and other vesicular diseases, and 
increased incidence has been seen in the United States and other swine producing countries since 
2014. Diagnostic testing must be utilized to confirm infection. The VP1 protein of SVA is a 
component of the viral capsid which has been used in serologic testing and proven highly 
immunogenic in other members of the Picornavirus family. Affected and non-affected animals 
from areas of clinical outbreak have been proven seropositive for IgG against SVA-VP1. In this 
study, an ELISA using VP1 was completed to determine the seroprevalence of virus antibody in 
United States’ swine. A mouse model was explored for use in pathogenicity and transmission. 
SVA polyclonal antibodies and SVA recombinant VP1 monoclonal antibodies were generated and 
characterized through ELISA, western blot, IFA, and viral neutralization. 
 Serum was collected from 2,433 clinically healthy sows and 3,654 clinically healthy 
grower or finisher pigs residing at 219 unique commercial swine production sites. SVA 
seroprevalence was evaluated by SVA rVP1 ELISA and SVA IFA. The estimated seroprevalence 
for grower-finisher pigs and sows was 12.2% and 34.0%, respectively. The herd prevalence was 
42.7 % for grower-finisher farms and 75.8% for sow farms. The SVA rVP1 ELISA and SVA IFA 
exhibited a fair (sows) and moderate (grower-finisher) agreement at the herd level, while a fair 
agreement was observed at the individual level for both pig categories evaluated. The McNemar’s 
test was significant at the individual and herd level (p < 0.05). In this study, we demonstrated the 
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presence of SVA IgG antibodies in pigs from clinically healthy grower-finisher and sow herds. 
These results suggest that SVA is circulating subclinically in sow farms and grower-finisher pig 
farms in major swine producing states in the United States.  
 Five strains of mice were injected subcutaneously with virus. Then, route of inoculation 
was explored. Animals were monitored daily. Samples were tested by PCR, ELISA, and IFA to 
examine viral presence. No mouse showed clinical signs. However, feces and tissue of infected 
animals tested positive for virus specific nucleic acid. Seroconversion and a transient viremia 
occurred in mice inoculated by subcutaneous or intraperitoneal route. Mice develop subclinical 
infection when inoculated with SVA and may play a role in the transmission of SVA as a vector 
or reservoir for disease. 
Eighteen epitopes of the VP1 protein were formed and their reactivity tested through 
indirect and blocking ELISA. Polyclonal antibodies and monoclonal antibodies were generated 
and utilized to identify reactive epitopes of the SVA VP1 protein. Four regions of the SVA-rVP1 
protein showed high reactivity in multiple testing platforms. Results suggest that immune response 
generated by SVA-VP1 in mice can be defined by a set of linear epitopes that may be involved in 
the activity of antibody. 
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 CHAPTER 1. GENERAL INTRODUCTION 
Introduction 
 Senecavirus A (SVA) is a non-enveloped, single-stranded RNA virus in the family 
Picornaviridae. It is the only member of the genus Senecavirus (1). The virus is composed of four 
structural proteins (VP1-4) in an icosahedral capsid and was originally discovered in 2002 as a 
contaminant in cell culture (2). SVA has been associated with vesicular disease and increased 
neonatal mortality of swine in multiple countries. The extension and distribution of vesicular 
lesions is indistinguishable from other vesicular diseases including foot and mouth disease virus 
(FMDV), vesicular exanthema of swine (VES), swine vesicular disease (SVD), and vesicular 
stomatitis. The clinical similarity between SVA and other vesicular disease calls for a foreign 
animal disease investigation at every outbreak of vesicular disease, as FMDV, VES, and SVD are 
considered exotic for swine in the United States and have severe economic implications. SVA 
diagnosis is based on clinical signs, detection of the virus, and presence of antibody (3). The 
disease can also course subclinical and infected pigs can experience a transient viremia, viral 
shedding, and antibody response without evidence of clinical disease (4).  
Virus structure 
 Members of the family Picornaviridae are characterized by their non-segmented, positive 
sense single stranded RNA genome. SVA contains a genome approximately 7.2 kb in length and 
follows a layout typical to the Picornaviruses: leader, four polypeptides of P1, three polypeptides 
of P2, and four polypeptides of P3 (5, 6). The RNA genome shows an internal ribosome entry site 
(IRES) similar to classical swine fever virus and Hepatitis C classified as type IV IRES (5, 7). The 
IRES element, located at the 5’ end, assists in cap-independent initiation of protein synthesis (5). 
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These structural and functional resemblances in the IRES between other virus families suggest that 
genetic exchange between viruses of the Picornaviridae and Flaviviridae family occurred in 
persistently co-infected pigs (7).  
The amino acid sequence of the original, historical SVA isolate (SVV-001) is most similar 
to the cardioviruses in the family Picornaviridae, with a 35.8% sequence homology (2). The 7,280 
base genomic RNA is classified under Genbank Accession No. DQ641257. This encodes a 5’ 
untranslated region (UTR) 666 bases in length, 4 structural proteins and 7 non-structural proteins 
matured from polyproteins, then a short 3’ UTR 70 bases in length (5). SVA viral proteins are 
encoded by the single stranded RNA genome that is translated into one polyprotein. This 
polyprotein is modified pre- and post-translationally by viral proteases. The 5’ end of the genome 
contains covalently bound VPg and encodes structural proteins, while the 3’ end has a poly(A) tail 
and codes for non-structural proteins. SVA replicates at a rapid pace in the cytoplasm of host cells. 
The P1 region is translated and cleaved by 3C protease, yielding VP0, VP3, and VP1. VP0 is 
further processed into VP2 and VP4. VP1, VP2, and VP3 interlace on the external surface of the 
capsid, with VP4 located internally. The P2 region encodes for 2A protein, which is predicted to 
play a role in ribosome-skipping. The 2B protein is dissimilar to other picornaviruses in its primary 
sequence structure and its function is unknown. The 2C protein is similar to helicase and acts in 
RNA synthesis. The P3 region of the SVA polypeptide encodes 3A polypeptide and little is known 
regarding its function. Protein 3C is an enzyme with chymotrypsin-like activity. The 3D 
polyprotein acts in conjunction with 3AB and 3C in virus replication, uridylation, and as a 
component of RNA-dependent RNA polymerase (5).   
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The capsid structure of SVA is approximately 30 nm in diameter and is comprised of 60 
protomers arranged in an icosahedral manner (8). Each protomer is composed of four structural 
proteins: VP1, VP2, VP3, and VP4. These proteins have a length of 263, 284, 239, and 72 residues, 
respectively (8). They show a similar folding pattern to structural proteins in other members of 
Picornaviridae. Sixty copies of each protein interlace to create the icosahedral capsid. The capsid 
of many picornaviruses contains depressions that play a role in receptor binding and evasion of 
host immune surveillance. The pocket of Senecavirus is similar to that of cardioviruses; the 
hydrophobic pocket does not contain a lipid pocket factor (9-12). However, unlike cardioviruses, 
the entrance to the SVA pocket is almost entirely sealed off by residues of the VP1 protein. 
Compared to other picornaviruses, characteristics of the SVA capsid proteins are more 
pronounced, including the BC loop, loop II, and the FMD GH loop of VP1; the puff of VP2; and 
the knob of VP3. The VP4 protein interacts with internal nucleic acid (8). Additionally, SVA 
produces an empty procapsid and full virion particles during infection, both of which possess 
matching antigenic properties. It should be noted that the procapsid appears to require genomic 
RNA for stabilization during environmental stressors. Changes in the procapsid could allow for 
construction of a swine vaccine or nano-carrier in human cancer treatment (13). 
History 
 Seneca Valley Virus (SVV-001) was detected as a contaminant in PER.C6 fetal retinoblast 
cell culture in 2002 at Genetic Therapy Inc. in Gauthersburg, Maryland, USA, close to the Seneca 
Valley geographic region. It is believed that the virus was introduced into cells through bovine 
serum or porcine trypsin used in cell culture media. The cell culture was cultivating adenovirus-5 
based vectors when a rapid onset of cytopathic effect was observed less than 24 hours after 
infection. SDS-PAGE and electron microscopy yielded the classification of SVV-001 as a 
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Picornavirus (5). Virus isolates were found retrospectively in samples collected from healthy pigs 
in United States beginning in 1988 (14). In 2016, the International Committee on Taxonomy of 
Viruses (ICTV) renamed the only species within the genus Senecavirus from Seneca Valley Virus 
to Senecavirus A (https://talk.ictvonline.org/ictv-reports/ictv_9th_report/positive-sense-rna-
viruses-2011/w/posrna_viruses/234/picornaviridae. Accessed, March 5th, 2018). 
During the 1980s, cases of vesicular disease in swine were reported in New Zealand (15, 
16) and Australia (17). Although the etiology is still unknown and SVV was not completely ruled 
out, these cases were associated with contact to vegetation contaminated with the fungus 
Sclerotinia sclerotiorum and feeding marine products, respectively. Meanwhile, an outbreak of 
vesicular disease of unknown etiology was reported in Florida, United States (18). In 2004, a break 
of vesicular diseases causing lesions on the snout, oral cavity, and coronary bands was reported 
affecting pigs at several sites of a farrow-to-finish operation in Indiana. A foreign animal disease 
investigation yielded negative results for foot and mouth disease virus, swine vesicular disease, 
vesicular stomatitis, and vesicular exanthema of swine by PCR and several serological methods. 
The etiology in of this outbreak was not determined, and the clinical signs termed porcine 
idiopathic vesicular disease (PIVD) (19).  
Although the role of SVA was still unknown in 2007, SVA was detected by PCR for the 
first time in vesicular lesions in finisher hogs imported from Canada to a packing plant in 
Minnesota (20). In 2012, another report of SVA in association with the presence of vesicular lesion 
was made in a boar with a spontaneous outbreak of vesicular lesions after purchase at the Indiana 
State Fair (21). Several swine sites in Brazil reported vesicular lesions from November 2014 to 
early 2015 (22). Vesicular fluid, skin scraping, and cutaneous samples from affected and 
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asymptomatic pigs were evaluated for SVA and other vesicular disease. During this outbreak the 
development of a specific RT-PCR, targeting the VP1 protein with no cross reaction to other 
members of the Picornaviridae family, allowed SVA detection from clinically affected animals. 
These outbreaks represented the first documented cases of SVA outside of North America (23). 
Some herds also described increased neonatal losses (30-70%) of piglets one to four days of age, 
termed epidemic transient neonatal losses (ETNL). Each outbreak was self-limiting and lasted one 
to two weeks. The University of Minnesota Veterinary Diagnostic Laboratory received samples 
from vesicular swabs and were able to generate a full-length sequence of the virus. The strains 
shared 94.2-96.5% nucleotide identity to the previously documented SVV-001 genome (22). 
Interestingly, a serological retrospective study demonstrated that no circulating antibodies were 
present in the major swine production states in Brazil prior 2014 (24).  
During July 2015, an increased incidence of vesicular disease outbreaks was observed in 
exhibition swine, commercial finisher sites, and breeding herds in Iowa (25, 26). Animals showed 
acute lameness and coronary band vesicles without mortality (27). Further cases have since been 
documented in Iowa and Ohio (28, 29). Increased pre-weaning mortality and neonatal lethargy 
were also reported on multiple producer sites (30). The genomic sequence of three isolates revealed 
93.9-94% nucleotide identity to SVV-001 (31), 95.9-96.1% identity to a Canadian isolate, and 
97.7-97.9% identity to Brazilian isolates (26). The United States isolates appeared to belong to 
new clade of SVA, with distinct VP1 sequences from those in other countries (27). Sampling of 
healthy animals moving to cull swine markets indicated that SVA was circulating, and the US 
strain was most similar to that isolated in Brazil causing vesicles and ETNL (32).  
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The first reports of SVA in China were made in 2015. Two farms broke with vesicular 
lesions and lameness, with SVA detected by RT-PCR. Illness spread to surrounding pens, with 
some piglets displaying vomiting and fever. The sequence of the SVA isolate was most similar to 
the United States and Brazilian strains (33, 34). Currently there are multiple strains of SVA thought 
to be circulating in China (31, 35) and more recent Chinese strains have shown residue shifts in 
the VP1 protein creating a divergence of two clusters among local strains.  
In February 2016, swine in Colombia broke with vesicular lesions attributable to SVA, 
with a 98.5-98.9% nucleotide identity to the US strains (KX857728) (36). SVA was next detected 
in swine in Thailand in October 2016, where vesicular lesions were reported and SVA isolated. 
The two isolates described in Thailand were most similar (98.2% sequence homology) to Canadian 
strain 11-55910-3, with substitutions in the VP1, 3D, and 3A genes (37). Early in 2018, SVA 
appeared in Vietnam, causing vesicular lesions and showing a 98.5-99% homology with Chinese 
strains (KX173339, KX173338, KX173340, KY038016) (38).  
Since its discovery, SVA has been identified as a cell culture contaminant, a virus causing 
with vesicular lesions, and a pathogen associated with neonatal losses. It has been attributed with 
outbreaks in multiple swine producing countries, with cases appearing in new locations each year. 
SVA appears to be on the path to becoming a virus with global prevalence. 
Clinical signs and lesions associated with SVA infection 
 SVA specific neutralizing antibodies have been detected in swine, cattle, and mice. 
However, these antibodies have not been detected in humans (14). Viral particles were also 
detectable in swine tissues, mouse feces and intestines, houseflies, and environmental samples 
(39), but cattle samples proved negative for SVA particles on RT-PCR. 
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 The signature clinical sign of SVA is vesicular lesions on the nose and coronary band, 
leading to anorexia and lameness in 10-90% of pigs (25). Clinical disease associated with SVA 
was first described in swine in 2007. Finisher pigs from Canada processed in a packing plant in 
Minnesota developed vesicles along snout, coronary band and lameness. The vesicles were a few 
millimeters in diameter and filled with abundant translucent fluid. Occasionally vesicles were 
ruptured, presenting with round, necrotic edges. Other animals had red, coalescing erosions or 
swollen, blanched coronary band lesions. No pyrexia was observed and other causes of vesicular 
diseases were ruled out through testing at Plum Island Animal Disease Center (40). In Brazil, 
additional clinical signs were reported in piglets, beginning in 2015. Increased neonate mortality 
was found in association with SVA in multiple regions. These piglets were in the first week of life 
and experienced a variety of signs including weakness, salivation, cutaneous hyperemia, 
neurologic signs, diarrhea, and sudden death. These clinical signs lingered for 3-10 days before 
ceasing in surviving piglets. Necropsy revealed petechial hemorrhage of the kidneys, tongue 
ulceration, and coronary band vesicles (41).  
 Affected skin displayed orthokeratotic and parakeratotic hyperkeratosis, epidermal 
hyperplasia, ulceration, and infiltration of neutrophils and cellular debris (21). Experimentally 
infected finisher pigs had multifocal dermal separation with infiltration of inflammatory cells, 
necrotic keratinocytes, hemorrhage, and fibrin accumulation. In the first 3-7 days after infection, 
lymphoid hyperplasia was observed in the tonsils, spleen, and lymph nodes, while the lungs 
contained mild atelectasis and congestion (42). Microscopic lesions have not been found 
consistently in other tissues of affected animals (21).  
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Among piglets, common histopathologic lesions included interstitial pneumonia and 
ballooning degeneration of the urinary bladder and renal pelvis epithelium, with rare 
intracytoplasmic eosinophilic inclusion bodies (41). Atrophic enteritis of the small intestines was 
also observed, mirroring the diarrheic gastrointestinal contents found on gross necropsy. A 
nonsuppurative meningoencephalitis and choroid plexitis was noted in some animals experiencing 
ETNL. Skin lesions of these piglets were similar in character to those of adults, with 
hyperkeratosis, necrosis, and crusting of the dermis (43, 44). 
 Inoculation of swine with contemporary SVA strain SD15-26 by oronasal route caused 
vesicular disease in 15-week-old finisher pigs. Experimental inoculation resulted in lameness and 
lethargy persisting for 2-10 days, with vesicles observed beginning 4 days post inoculation (dpi). 
These areas began as regions of epidermal erythema, developing into vesicles 0.5-3 cm in 
diameter. After rupturing at 5-6 dpi, vesicles resulted in areas of epidermal erosion, ulceration 
covered by an epidermal crust. Lesions self-resolved by 12-16 dpi (42). Similar results were 
obtained with intranasal administration of SVA to 9-week-old nursery piglets: early development 
of vesicular lesions causing mild lameness. In these younger piglets, coronary band lesions were 
observed beginning 4 dpi, with snout and lip lesions occurring at 5-6 dpi (45). 
 SVA infection in other species seem to have a subclinical presentation. Experimental 
studies exploring the oncolytic effect of SVA utilizing murine models noted no clinical signs or 
lesions related to virus administration (46). No clinical signs have been observed in seropositive 
cattle (14) nor humans in clinical trials (47, 48), suggesting that swine act as the natural host for 
SVA infection. 
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Pathogenesis 
 The specific mechanism of cell entry and receptors associated with SVA causing clinical 
infection in pigs is still unknown. In vivo studies have been completed in swine and mice with the 
only observable viral replication occurring in the epidermis, tonsillar dendritic cell and 
macrophages in lymph nodes. In vitro studies have utilized swine testis (ST), swine kidney (SK-
RST and PK-15), and human small-cell lung cancer cell lines (NCI-H1299) (14, 49-51) and 
demonstrated that SVA presents several motifs similar to putative domains present in foot and 
mouth disease. However, all of these domains have an intracytoplasmic location, and may require 
joint activity (8). SVV-001 has been tested by in vitro loss-of-function tests in human cancer cell 
lines to identify anthrax toxin receptor 1 (ANTRX1), also known as tumor endothelial marker 8 
(TEM8), as an essential receptor for SVV infection (52, 53). The virus utilizes TEM8 as a 
transmembrane glycoprotein for cell entry, which is upregulated on tumor cells and bind type VI 
collagen to promote tumor growth; however the role of TEM8 in vivo is still unclear (54). In 
addition, SVA infection does not affect  the immunoglobulin receptors superfamily-like most other 
picornaviruses (55). During SVA infection in vitro, interferon α and interferon β signaling is 
downregulated in permissive cells. This is a common trait in certain cancer cell lines (52).  SVV-
001 blocks type 1 interferon (IFN) signaling to evade the host innate immune response. Infection 
does not directly cause an IFN response. Instead, expression of interferon regulatory transcription 
factor (IRF3) and IRF7 inhibit IFN. The virus targets mitochondrial antiviral signaling protein 
(MAVS), TIR-domain-containing adapter-inducing interferon-β (TRIF), and tumor necrosis factor 
receptor-associated factor family member-associated NF-κβ (TANK) adaptors of the host cell with 
3Cpro to signal shutdown of the IFN response and activate the janus kinase signal transducer and 
activator of transcription proteins (JAK-STAT) pathway (56, 57). Additionally, the retinoic acid-
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inducible gene 1 (RIG-1) knockout has also been associated with increased SVV replication and 
propagation, through decreased IFN signaling (58), suggesting the gene involvement in infection. 
Experimental studies in vivo showed that a field isolate, collected from a clinically affected 
pig with vesicular disease, administered by oronasal route to 15-week-old pigs caused lameness 
and lethargy 4 dpi. Vesicles, ranging from 0.5 to 3 centimeters diameter, developed on the coronary 
band and snout in 75% of experimentally infected animals. After 5-6 dpi, vesicles ruptured, 
progressing to dermal erosion and ulceration that healed completely by 12-16 dpi. SVA was 
detected by RT-PCR and in situ hybridization (ISH) in all dermal lesions. During this acute clinical 
presentation viremia spanned 3-10 dpi. An acute seroconversion was also observed with detectable 
IgG antibodies by 10 dpi. The IgG response possessed neutralizing activity. Viral shedding was 
detected by PCR in oral and nasal secretions to 28 dpi, and in feces from 3-14 dpi. The presence 
of SVA in lymph nodes and tonsil was confirmed by RT-qPCR, virus isolation, and ISH. 
Histological changes associated with SVA infection were seen only in cutaneous lesions. Lesions 
were characterized by multifocal separation of dermis from epidermis, necrotic keratinocytes, 
fibrin, and inflammatory cells. In addition, there was also mild follicular hyperplasia in superficial 
lymph nodes (59). Clinical evaluation has also shown that the virus can be present subclinically. 
In sows, 50.75% of animals belonging to a herd experiencing a clinical outbreak had positive RT-
qPCR of tonsil swabs, while the virus was detected in tonsillar swabs only in 28.12% of their 
piglets. Although a high percentage of sows were positive by RT-qPCR, only 50% of the positive 
animals presented with vesicular lesions and clinical signs of SVA infection. No significant 
differences were observed in viremia or viral shedding in feces and oral fluids in piglets born from 
clinically or subclinically infected sows. Additionally, all sows developed an SVA-specific IgG 
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response in the six weeks following the outbreak, while 42.8% of piglets from clinical sows and 
63.6% of piglets from non-clinically affected sows seroconverted during that time (4).  
After a clinical re-emergence of SVA in 2015, phylogenetic evaluation has demonstrated 
that the virus has gone through genetic variation affecting several structural and non-structural 
proteins. A pathogenesis comparison study evaluated the historical SVV-001 and contemporary 
SVA strains in pigs. It was observed that SVV-001 had a lower virulence when compared to a 
SVA strain isolated from vesicular lesions. The historical strain did not induce clinical disease, 
whereas the contemporary strain caused vesicular lesions in inoculated pigs. Nucleotide 
differences in the 5’ and 3’ UTRs and long polyprotein-encoding ORF may play a part in this 
virulence difference. Despite the difference in clinical presentation, cross-reaction of neutralizing 
antibody and T cell responses were observed, suggesting conservation of antigenic regions (60). 
Piglets less than one week of age experiencing disease associated with SVA ETNL, showed 
interstitial pneumonia; lymphoid depletion in the spleen, tonsils, or lymph nodes; ballooning 
degeneration of urinary bladder epithelium; and atrophy of intestinal villi. The lymph nodes of 
newborn pigs with natural infection possessed the highest viral load (61).  The virus has been 
detected by ISH in the transitional epithelium in the kidney and ureters, cerebral choroid plexus, 
and tongue. In animals presenting with diarrhea, the virus has been demonstrated by 
immunolabeling in cells of the laminal propria of the small intestine. Further confirmation of SVA 
by ISH and genome amplification from neonates with enteric signs suggest that the virus may 
disseminate in newborn pigs by an enteric-neurological method, and then spread by urine and 
gastrointestinal secretions (62, 63). Although it has not been experimentally demonstrated, it seems 
that SVA may be vertically transmitted, similar to foot and mouth disease (64).  
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Immune Response 
 In experimentally inoculated 15-week-old pigs, the presence of neutralizing antibodies 
were first detected at 5 dpi, with maximum concentration observed between 7 and 14 dpi. This 
increment in neutralizing antibody concentration was associated with reduction of viremia during 
the first two weeks post infection. Both antibody isotypes IgM and IgG were detected by IFA at 5 
dpi and 7 dpi, reaching a maximum concentration at 10 and 14 dpi, and becoming undetectable by 
21 and 25 dpi, respectively. It has also been observed that the dynamic of the IgM antibodies 
correlated with neutralizing antibody levels. The humoral immune response was further assessed 
using fluorescent microsphere immunoassays (FMIA) against structure proteins VP1, VP2, and 
VP3. The FMIA demonstrated that the presence of IgM and IgG was strongly associated with 
structural proteins VP2 and VP3 (50, 65). IgG levels in sows increased two to three weeks after 
onset of clinical signs and remained elevated until six weeks after onset. No study has monitored 
the IgG levels past this time. In naturally infected sows, specific SVA IgG was present one week 
after clinical outbreak. During this clinical evaluation, no differences were observed in the 
antibody dynamic nor levels of IgG between clinically affected and non-affected animals; in 
addition, piglets born from seropositive sows showed high IgG levels at 7 days of age, with no 
significant difference based on the sows’ clinical status. These antibody levels declined and 
disappeared by approximately 6-7 week of age, suggesting that maternal colostrum is involved in 
neonatal protection rather than an active immune response (4).  
SVA infection can also induce a strong cellular immune response. Experimentally infected 
animals have shown IFN-γ specific T-cells as early as 3-7 dpi. The T cell phenotype observed 
during SVA infection is also characterized by an early and stronger CD4+ cells response compared 
to CD8+. The dynamic of the CD4+ response correlates with the humoral response and more 
13 
 
specifically with the presence of neutralizing antibody, while CD8+ T cell activity correlated with 
resolution of clinical signs and viral clearance from replications sites such as the skin. However, 
T cell responses did not correlate with viral clearance from the tonsils and lymph nodes, and viral 
RNA remained detectable in this these tissues at 14 dpi. Double positive CD4+CD8+ T cells were 
stimulated by SVA infection and caused an IFN response. This subset of T cells was detected after 
35 dpi, past the resolution of clinical disease, suggesting a role as SVA-specific memory T cells. 
Both αβ- and γδ-T cells were specifically found in response to VP1, VP2, and VP3 structural 
proteins at similar frequencies, with a slightly higher response to VP2 (65).  
Currently there are no prevention strategies for SVA introduction and no protection 
methods outside of husbandry and biosecurity. One experimental vaccine study has been 
completed, in which a strain of SVA isolated in China was inactivated using binary ethylenimine 
and mixed with oil adjuvant. One dose of vaccine yielded neutralizing antibody in pigs, and 
vaccinated animals showed no clinical signs after virus challenge (66). Work by Li et al. suggests 
that use of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-
associated protein-9 nuclease (Cas9) genome editing could be used for cell modification to create 
an efficient virus cell line for vaccine production (58).  
Epidemiology and Transmission 
 The clinical presentation of SVA seems to be associated with multiple factors. During 
clinical outbreaks it has been demonstrated that not all infected animals develop vesicular lesions 
and animals can remain subclinical, suggesting that other factors are necessary to cause disease. 
In addition, there is no correlation between both SVA clinical presentations. Not all farms 
reporting PIVD also report ETNL, and only some herds with SVA associated ETNL report 
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vesicular disease. ETNL in Brazil broke in clusters, even in closed herds. Although is not clear, 
after the first natural exposure affected farms may develop herd immunity since there are no 
official reports of clinical re-breaks (67). Risk of SVA infection has a high variation between herds 
and farm types. Risk factors may include a high number of breeding females, more employees, 
and biosecurity gaps (25). Commingling of piglets at the time of weaning may contribute to spread 
of SVA (68).  Accelerated hydrogen peroxide has shown efficacy in disinfecting areas 
contaminated by SVA. (69). 
Although swine are the only natural host of SVA, clinical studies have shown that rodents 
and insects can contribute to the spreading of the virus. During these studies the virus was detected 
by RT-qPCR on mouse fecal samples, mouse small intestine, and fly samples. SVA presence was 
later confirmed by virus isolation. During the same clinical evaluation, the virus was detected from 
swabs of internal and external surfaces on the farm. This suggested that SVA may remain viable 
in the environment, as well as in mice, which may act as natural reservoir and a potential vector 
(70). 
Samples collected from swine and their environment at several sites over a twelve-month 
period from 2015 to 2016 showed that high genetic diversity occurs in SVA over a short time 
period. Although most of the differences were synonymous, nonsynonymous changes were present 
in VP1-VP3 regions, 3A, 3C, and 3D. It has been proposed that mutation pressure acts as the main 
driver of SVA evolution, rather than natural selection (71). It is not yet clear if these structural 
changes may increase the virulence of the virus in the host; however SVV-001 monoclonal 
antibodies were not able to bind all these new mutated strains, indicating that changes in binding 
site may affect the hosts’ humoral protection (72).  
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Diagnosis 
 The diagnosis of SVA infection can be achieved by direct and indirect pathogen detection 
(Table 1). Based on the characteristic cytopathic effect of SVA infection, traditional virus isolation 
has been reported in PER.C6 fetal retinoblast cells (8), PK-15 cells (23), swine testis cells (26), 
H446 small cell carcinoma cells (73), and H1299 human non-small cell carcinoma cells (59). 
Cytopathic SVA can be isolated from vesicular swabs and scrapings (27).  
The detection of SVA nucleic acid by RT-PCR has improved in diagnosis and helped to 
understand the pathogenesis of this virus. Numerous RT-PCR assays with different viral targets 
have been reported and are currently available. A RT-qPCR has been developed for the SVA 3D 
polymerase gene (74) and is available as a commercial kit (Tetracore, Inc., Rockville, MD). A 
Taq-man based RT-qPCR for a conserved region of the VP1 protein (75) and a nested RT-PCR 
assay (76) have also been described in detail. A reverse transcription loop-mediated isothermal 
amplification (RT-LAMP) assay has been described as a method for rapid detection that could be 
used in the field for SVA diagnosis (77, 78).  
Although viremia is relatively short and does not last more than 10 days in experimentally 
infected animals, nucleic acid can be detected by RT-PCR. SVA RT-PCR detection in serum 
during clinical break has demonstrated that infection can occur subclinically (79). PCR detection 
has helped to determine viral shedding in feces and oral fluids. Although during the viremic phase 
of the disease, RT-PCR can detect the virus in almost all tissues from affected animals, after 
viremia disappears this technique is not capable of detecting the virus outside of a high burden in 
the tonsils and lymph nodes.  
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The virus can also be detected in situ by ISH and IHC.  Specific RNA probes targeting 
areas of the VP1 gene demonstrated the presence of SVA in vesicular lesions of affected sows, 
ulcerative lesions in the tongue of piglets, and various other tissues with no evidence of histological 
lesions (80). The RNAScope ISH technique was capable of detecting virus in situ in SVA PCR 
positive sample ranging from 12 to 32.6 Ct.  Monoclonal antibodies have been used for IHC 
detection. In neonates without specific vesicular lesions associated with ETNL, viral antigen has 
been detected in the transitional epithelium of the renal pelvis and urinary bladder, as well as the 
choroid plexus, enterocytes, and tongue of piglets (81). A serum neutralizing assay has also been 
described for diagnosis of infection (82). 
Experimental studies have shown that after five dpi SVA specific antibodies can be 
detected in serum. Different structural proteins including VP1, VP2 and VP3 have been evaluated 
as potential antigen targets in swine serum for IgG detection through indirect ELISA. While the 
VP3 protein showed minimal immunoreactivity, both VP1 and VP2 reacted with serum from 
naturally infected animals (83). A VP1 indirect ELISA yielded a sensitivity of 93% and a 
specificity of 99% (4). The VP2 protein ELISA was optimized and validated, with 94.2% 
sensitivity and 89.7% specificity. IFA testing of swine serum showed similar results, with 
increased sensitivity of the ELISA test during early infection (83). Cross-reactivity has been 
demonstrated between historical SVV strains and contemporary SVA strains (60). Comparative 
serological studies have shown that a competitive ELISA using mAbs decreased cross-reactivity 
and allow a more rapid test conclusion than IFA (50, 84). 
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Oncolytic Properties 
Due to its cytopathic effect on cell culture, mostly in neoplastic cell lines, SVA was proven 
to possess oncolytic properties and has been under investigation as virotherapy for cancer in 
humans. Some of the characteristics that make this virus desirable for oncolytic treatment are: 1) 
the virus does not contain a DNA phase during replication, therefore cannot integrate into the 
mammalian genome; 2) no insertional mutagenesis was noted after several cycles in vivo 
replication; 3) the virus can induce apoptosis in neoplastic cells;  4) this RNA virus showed a 
tropism for oncogenic cells;  5) SVV-001 has demonstrated an ability to target and enter solid 
tumors after intravenous administration.  
Senecavirus was able to enter neuroendocrine tumor cells and cause cytotoxicity. SVV-
001 possessed the ability to cause cytopathic effects in neuroblastoma, rhabdomyosarcoma, 
medulloblastoma, Wilms tumor, and glioblastoma cells (2, 85, 86). The virus required α2,3- and 
α2,6- linked sialic acids to infect pediatric glioblastoma multiforme cells (46). Importantly, after 
viral therapy to human cancer patients, SVA posed a small risk of excretion. The risk of animal 
infection from humans due to viral excretion was less than 1% (87). Early phases of testing for 
safety and clinical efficacy began in adult and pediatric cancer patients. Neotropix started 
development of SVV-001 as drug NTX-010 with Alliance for Clinical Trials in Oncology and 
United States national Cancer Institute. Acting to stimulate apoptosis, Phase I trials were 
completed on neuroendocrine tumors in 2010 (88). Phase II trials were conducted on small cell 
lung cancers (89) and presented in 2013 at the Annual Meeting of the American Society of Clinical 
Oncology. An infectious clone of the virus was able to enter only a small population of small cell 
lung carcinoma cells and target these cancer cells in mice with tumors (73). However, in 2017, 
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these phase II trials were ended as several studies demonstrated no efficacy in late state disease 
(http://adisinsight.springer.com/drugs/800024958, accessed 7/25/2017).  
Thesis Formatting 
This thesis contains five chapters. The first chapter introduces the project, with a critical 
review of literature that is currently available regarding Senecavirus A. The second chapter 
discusses the seroprevalence of Senecavirus A in the United States’ swine producer herds. In the 
third chapter, a mouse study for pathogenicity and transmission of the virus is described. The 
fourth chapter describes a project in determining the immunodominant regions of Senecavirus A-
VP1 protein through use of ELISA epitope mapping and other techniques. The fifth chapter 
provides a summary and general conclusion of the projects discussed in this thesis.  
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Tables 
Table 1- Multiple direct and indirect detection methods are under research for SVA. 
SVA Test Published 
ELISA (VP1) Gimenez-Lirola et al, 2017 Journal of Clinical Microbiology 
Dvorak et al, 2017 BMC Research 
ELISA (VP2) Dvorak et al, 2017 BMC Research 
ELISA (VP3) Dvorak et al, 2017 BMC Research 
ELISA (WV) Data not published 
cELISA Goolia et al, 2017 Journal of Veterinary Diagnostic Investigation 
IFA Goolia et al., 2017 Journal of Veterinary Diagnostic Investigation 
Dvorak et al., 2017 BMC Research 
Joshi et al., 2016 Journal general Virology  
Montiel et al., 2016 Emerging Infectious Disease 
VNT Goolia et al., 2017 Journal of Veterinary Diagnostic Investigation 
Saporiti et al., 2017 Veterinary Research Communication 
Joshi et al., 2016 Journal general Virology  
ISH Joshi et al., 2016. Journal of General Virology 
IHC Leme et al., 2016. Journal of Comparative Pathology 
PCR Bracht et al., 2016., PLoS One 
Fowler et al, 2017. Journal of Virological Methods 
Dall Agnol et al., 2017. Molecular Cell Probes 
Feronato et al., 2017.Tropical Animal Health and Production 
RT-LAMP Armson et al., 2018. Transboundary and Emerging Diseases 
Zeng et al., 2018. Journal of Virological Methods 
 
WV= SVA whole virus, cELISA= competitive ELISA, IFA=immunofluorescence assay, VNT= virus neutralization test, ISH= in 
situ hybridization, IHC= immunohistochemistry, RT-LAMP= reverse transcriptase loop-mediated isothermal polymerization 
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 Abstract 
Senecavirus A (SVA) is a single-stranded RNA virus in the family Picornaviridae. 
Recently, SVA has been associated with idiopathic vesicular disease and increased neonate 
mortality outbreaks in the United States, Brazil, China, Colombia, and Thailand, with increasing 
incidence since 2014. Indirect detection by antibody detection methods, including indirect 
immunofluorescence assay (IFA), virus neutralization assay, and competitive or indirect enzyme-
linked immunosorbent assays (ELISAs), have been reported in clinical and experimental trials. 
The objective of this study was to determine the seroprevalence of SVA in nonclinically affected 
herds in the United States. Individual samples were collected from 3,654 and 2,433 clinically 
healthy grower-finisher pigs and sows, respectively, from 219 unique commercial swine 
production sites. SVA seroprevalence was evaluated by SVA rVP1 ELISA and SVA IFA. The 
estimated seroprevalence for grower-finisher pigs and sows was 12.2% and 34.0%, respectively. 
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The herd prevalence was 42.7 % for grower-finisher farms and 75.8% for sow farms. The SVA 
rVP1 ELISA and SVA IFA exhibited a fair (sows) and moderate (grower-finisher) agreement at 
the herd level, while a fair agreement was observed at the individual level for both pig categories 
evaluated. The McNemar’s test was significant at the individual and herd level (p < 0.05). In this 
study, we demonstrated the presence of SVA IgG antibodies in pigs from clinically healthy 
grower-finisher and sow herds. These results suggest that SVA is circulating subclinically in sow 
farms and grower-finisher pig farms in major swine producing-states in the United States.  
 
Key Words: Senecavirus A, SVA, seroprevalence, SVA recombinant VP1 indirect ELISA, SVA 
immunofluorescence assay  
Introduction 
Senecavirus A (SVA) is a nonenveloped, single-stranded RNA virus of the genus 
Senecavirus in the family Picornaviridae (1). The virus possesses four structural proteins (VP1-4) 
composing an icosahedral capsid and seven nonstructural proteins (2). SVA was originally 
discovered as a contaminant in PER.C6 culture cells in 2002 and has been associated with swine 
idiopathic vesicular disease (IVD) in Canada and the United States (2, 3). However, retrospective 
studies demonstrated the presence of SVA in the U.S. swine population for over 30 years (4). Since 
2015, several outbreaks of IVD and epidemic transient neonatal losses (ETNL) associated with the 
presence of SVA have been reported in the United States (5, 6). In addition, numerous countries, 
including Brazil (7, 8), China (9, 10), Colombia (11), and Thailand (12), have reported an increase 
in the incidence of IVD cases associated with the presence of SVA. A phylogenetic analysis of the 
contemporary SVA isolated in the United States, Brazil, China, Thailand, and Colombia shows 
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small genomic differences (< 6%) compared with the historical Seneca Valley Virus strain (11-
15).  
The diagnosis of the disease should be based on the presence of clinical signs, detection of 
the virus, and presence of antibodies against SVA (16). Outbreaks of SVA IVD are characterized 
by abrupt onset of vesicles that progress to ulcerative dermatitis on the nostril and coronary bands, 
which affects a high percentage of sows and/or finisher pigs (6, 17). Lesions associated with SVA 
are clinically indistinguishable from those observed in foot-and-mouth disease, vesicular 
stomatitis, swine vesicular disease, and vesicular exanthema of swine. 
  Etiological diagnosis can be achieved by RT-qPCR, virus isolation from vesicular material 
(18, 19), in situ hybridization (20, 21), and immunohistochemistry (22). Antibody detection 
methods currently available include indirect immunofluorescence assay (IFA), virus neutralization 
assays, competitive enzyme-linked immunosorbent assays (cELISAs), and indirect ELISAs 
targeting different structural proteins (16, 19, 23-25). However, it has been demonstrated that 
animals can shed the virus and develop SVA-specific IgG response without evidence of clinical 
disease, suggesting that the virus may be circulating subclinically (16).  
 It has been demonstrated clinically and experimentally that SVA infection induces 
antibodies that can last for at least six weeks post infection, and the dynamic of antibodies detected 
during the infection may vary based on the antigen target of the serological test used (16, 20, 24). 
Thus, the presence of IgG against VP1 protein can be observed as early as 7-10 days post infection 
(dpi) (16, 24), whereas the response against VP2 seems to appear earlier, approximately 5 dpi, and 
can be detected for approximately 60 dpi (24).  In contrast, previous reports have shown a weaker 
and shorter IgG response to VP3, which lasted approximately only two weeks post infection (24). 
The duration of the detection of SVA IgG antibody by IFA has been reported to be between 10 
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and 40 dpi (19, 23, 25). Neutralizing antibodies also seem to appear early during infection, and 
they last for approximately seven weeks post infection (19, 23).  
There is no information currently available regarding the seroprevalence or virus 
circulation of SVA in commercial swine herds, particularly in those which have not reported 
outbreaks of SVA-associated vesicular disease or increased neonatal mortality. Therefore, the 
objective of this study was to determine the seroprevalence of SVA in grower-finisher and sow 
herds in the U.S. using a combination of two serological methods: SVA rVP1 indirect ELISA and 
SVA IFA.  
Materials and Methods 
Study design and recruitment of farms 
The study was carried out between June 2016 and December 2016, ensuring that all animals 
assessed were present in commercial production during the same time period, and encompassing 
one cycle of rearing market-value animals. Participants in the study were derived from commercial 
swine farms distributed across the major swine producing states in United States. Referral 
veterinarians or site manager were interviewed telephonically in order to assess if sites had not had 
a previous SVA diagnosis, a presence of detectable vesicular lesions, or an increase in neonatal 
mortality associated with the presence of SVA. After interview screening for clinically negative 
SVA farms, farmers (respondents) were asked for their cooperation and willingness to participate, 
and after that, a verbal consent was obtained. Those who were willing to participate were included 
in the study. No specific sampling was performed for this study and serum samples were selected 
from regular submissions for PRRSV monitoring received at the Iowa State University Veterinary 
Diagnostic Laboratory (ISU-VDL) and collected from clinically normal herds from multiple 
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geographic regions of the major swine-producing states (n = 18) that voluntarily agreed to 
participate in the study. Once serum samples or whole blood samples were received from the farm, 
samples were aliquoted and stored at -80°C until use. Submission samples were collected from 
breeding herds, gilt development units, farrow-to-finish operations, or wean-to-finish sites.  
Assuming a default 50% seroprevalence value with a 95% confidence interval and a 17% 
absolute error, it was calculated that it was necessary to include at least 30 animals from each site 
in the study (26). Each site was identified by a unique premise identification number and 
geographical location. The herd prevalence was presented by geographical regions as follow; 
Region 1: (North Dakota (ND), South Dakota (SD), Nebraska (NE), Minnesota (MN), Iowa (IA), 
Wisconsin (WI), Illinois (IL); Region 2: Michigan (MI), Indiana (IN), Ohio (OH), Pennsylvania 
(PA); Region 3: Wyoming (WY), Colorado (CO), Kansas (KS), Missouri (MO), Texas (TX), 
Oklahoma (OK), North Caroline (NC), Idaho (ID). Due to the lack of specific information 
regarding the age of the animals included in this study, the animals were grouped into two general 
categories: grower-finisher pigs (6–26 weeks of age) and sows (sows and gilts > 26 weeks old). 
Pigs under six weeks of age were not included in the study to avoid the detection of SVA 
circulating maternal antibodies (Gimenez-Lirola et al., 2016). All serum samples were tested by 
SVA rVP1 ELISA and SVA IFA.  
SVA recombinant VP1 indirect ELISA (SVA rVP1 ELISA) 
The SVA rVP1 ELISA used in this study has been described previously (16). In brief, 
NUNC MaxiSorp™ high protein-binding capacity polystyrene 96-well ELISA plates 
(ThermoFisher Scientific) were coated with rVP1 protein at 0.18 µg/ml. Positive and negative 
plate controls, SVA IgG antibody positive and negative serum samples, were run in duplicate on 
each ELISA plate. One-hundred µL of sera diluted 1:50 were added to each well and incubated at 
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37°C for 1 h. Plates were washed five times with 350 µL phosphate buffered saline containing 
0.1% Tween 20 (PBS-T) before adding 100 µL of horseradish peroxidase-conjugated goat anti-
swine IgG (Fc) antibody diluted 1:30,000. Peroxidase activity was monitored by adding 100 µL 
of tetramethylbenzidine-hydrogen peroxide (TMB) substrate solution (Surmodics, Eden Prairie, 
MN) for five min at room temperature in the dark. Then, 100 µl of stop solution (Surmodics) was 
added to each well and the plates were read (450 nm) using an ELISA plate reader (BioTek 
ELx800, Biotek® Instruments Inc. Winooski, VT, USA) operated with commercial software 
(GEN5TM, Biotek® instruments Inc.).  The serum IgG antibody response was represented as 
sample-to-positive (S/P) ratios. 
SVA immunofluorescence assay (SVA IFA) 
NCI-H1299 (ATCC® CRL-5803TM, Manassas, VA) cells were seeded (4 x 104 
cells/well) in 96-well clear-flat-bottom, black polystyrene surface-treated microplates 
(CellBIND®; Corning, Corning, NY) and grown in Roswell Park Memorial Institute 1640 medium 
(ATCC® 30-2001TM, Manassas, VA) supplemented with 5% heat-inactivated fetal bovine serum 
(FBS, ATCC®, Manassas, VA), 1% penicillin/streptomycin (GibcoTM, Thermo Scientific, 
Waltham, MA), and 100 μg/ml gentamicin (Gibco®TM), and incubated at 37°C with 5% CO2 for 
24 h.  Cell confluency was then evaluated using an imaging cytometer (SpectraMax® MiniMax 
300, Molecular Devices, Sunnyvale, CA) operated with SoftMax Pro 6.5 (Molecular Devices, 
Sunnyvale, CA) software. When confluency reached > 90% (± 2%), cells were inoculated with 
100 µl of SVA field isolate at 5,000 TCID50/ml mixed with the media described above but without 
FBS, and incubated at 37°C with 5% CO2. After 24 hours, the inoculum was removed and the 
cells were fixed with 80% acetone (50 μl/well) for 15 min at room temperature. Plates were air 
dried, sealed, and stored at -20°C until use. Cell confluency was re-evaluated and plates with < 
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90% cell confluency were rejected. Samples and controls (positive and negative) were tested in 
duplicate (100 µl/well) diluted 1:40 in phosphate buffered saline pH 7.4 (PBS; Gibco®, Thermo 
Scientific, Waltham, MA) with 0.1% BSA (Jackson ImmunoResearch, West Grove, PA), and 
incubated at 37°C for 1 h. After washing the plates three times with 200 μl of PBS (Gibco®), 50 
μl of DyLight® 650 anti-pig IgG (Abcam, Cambridge, MA) diluted in PBS (Gibco®) with 0.1% 
BSA (Jackson ImmunoResearch) was added to each well and incubated for 40 min at 37°C. Plates 
were then washed three times with 200 μl of PBS/well, followed by the addition of 100 μl of PBS 
per well before reading. Plates were read on the SpectraMax i3x® instrument operated with 
SoftMax Pro 6.5 (Molecular Devices, Sunnyvale, CA) software in image-acquisition mode, as 
follows: one site per well (4.32 mm2), wavelength 713 nm, 30 ms exposure, and -20 μm focus 
adjustment. 
Statistical analysis 
The cutoffs and associated diagnostic sensitivity and specificity for both SVA rVP1 ELISA 
and SVA IFA were estimated using samples of known SVA immune status collected and tested in 
a previous study (16).  For the SVA rVP1 ELISA, we selected an S/P cutoff of 0.4, giving a 
diagnostic specificity of 99.8% and 93% diagnostic sensitivity (16). For the SVA IFA, we used a 
1:40 serum dilution cutoff, which produce a diagnostic specificity of 98.2% and a diagnostic 
sensitivity of 95 to 100% between 3 to 4 weeks post-exposure (data not published). The diagnostic 
sensitivity and, more specifically, the time of detection and kinetic of the antibody detection varied 
with the post-exposure time (16, 20, 24, 27). Based on selected cutoffs, the overall prevalence and 
95% confidence interval (CI) was estimated for the total number of animals tested (n = 6087) in 
each group (grower-finisher and adults) for each serological test (SVA rVP1 ELISA and SVA 
IFA). In order to account for the lack of concordance between the results of the two diagnostic 
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assays in individual animals, the within-herd prevalence was also reported using parallel 
interpretation of the results of two diagnostic assays. However, in order to complement the 
potential lack of specificity introduced by parallel interpretation of tests within a herd, a farm was 
considered positive when at least two samples were positive either by SVA rVP1 ELISA or SVA 
IFA or combination of both tests. The herd prevalence and 95% CI was calculated for grower-
finisher pigs and adult pigs using SVA rVP1 ELISA and SVA IFA. To determine the individual 
and herd diagnostic agreement between SVA rVP1 ELISA and SVA IFA, a weighted Cohen’s 
kappa coefficient (k) with a 95% CI was calculated and interpreted as follows: poor, < 0.20; fair, 
0.20–0.39; moderate, 0.40–0.59; good, 0.60–0.79; and excellent, ≥ 0.80. Paired results of the two 
serological methods were analyzed by using McNemar’s Chi squared test to evaluate significant 
difference between the test results. Statistical analyses and geographical plots were performed 
using JMP 13.1.0 (SAS Institute Inc., Cary, NC, USA). The within-herd prevalence frequency for 
grower-finisher pigs and adult pigs was evaluated and plotted using GraphPad Prism® (GraphPad 
Software Inc., La Jolla, CA, USA). 
Results 
Senecavirus seroprevalence in grower-finisher pigs 
Serum samples collected from 3,654 grower-finisher pigs (6–26 weeks of age) in 131 
premises without previous history of SVA from 16 states throughout the United States were 
evaluated by SVA rVP1ELISA and SVA IFA. The overall seroprevalence based on SVA rVP1 
ELISA was 8.7% (CI ± 0.92; 7.83% to 9.67%), whereas the seroprevalence based on SVA IFA 
was 5.7% (CI ± 0.75; 4.95% to 6.45%). The overall prevalence obtained by a combination of both 
serological methods was 12.2% (CI ± 1.06; 11.18% to 13.30%). The herd prevalence was 27.3% 
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(CI ± 7.6; 19.74% to 34.94%) based on SVA rVP1 ELISA and 25.8% (CI ±7.46; 18.34% to 
33.26%) based on SVA IFA. The test agreement at the individual and herd level was fair and 
moderate respectively (Table 1), while McNemar’s test was significant at the individual (p = < 
0.001) and herd level (p= 0.009) (Table 1).  The estimated herd prevalence obtained using a parallel 
testing of SVA rVP1 ELISA and SVA IFA results (at least two positive animals either by SVA 
rVP1 ELISA or SVA IFA or both tests combined) was 42.7 % (CI ± 8.5; 34.2% to 51.1%). The 
frequency of farms with a within-herd prevalence ranging from 1% to 50%, from 51% to 70%, 
and from 71%–100% was 70.8%, 5.5%, and 1.8% respectively (Figure 1).  
The proportion of positive serum samples among the total grower-finisher pig samples tested 
by state is shown in Table 2. The three geographical regions showed similar herd prevalence 
(Figure 2). The geographical distribution of grower-finisher pigs showed that 15 of the 16 (93.7%)   
states included in this study were seropositive for SVA antibodies. No seropositive animals were 
detected in Texas (Figure 4). The highest concentration of positive results at individual and herd 
levels was found in the Midwest region of the U. S (Table 2; Figure 4). 
Senecavirus seroprevalence in adult pigs  
A total of 2,433 serum samples collected from clinically healthy sows and gilts (> 26 weeks 
old) without previous history of SVA, from 91 commercial production sites distributed over 18 
U.S. states, were evaluated by SVA rVP1 ELISA and SVA IFA. The overall prevalence obtained 
with each immunoassay was 26.2% (CI ± 1.76; 24.2% to 27.7%) by SVA rVP1 ELISA and 15.9% 
(CI ± 1.46; 14.5% to 17.4%) by SVA IFA. The overall prevalence calculated based on the 
combination of SVA rVP1 ELISA and SVA IFA results was 34.0% (CI ± 1.88; 32.1% to 35.9%). 
The percentage of seropositive farms was 71.4 % (CI ± 9.28; 62.15% to 80.71%) according to 
SVA rVP1 ELISA, 48.3 % (CI ± 10.27; 38.1% to 58.6%) according to SVA IFA, and 75.8% (CI 
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± 8.8; 67.0% to 84.6%) according to a combination of these serological methods. The agreement 
between SVA rVP1 ELISA and SVA IFA at the individual and herd level was fair (Table 1), while 
McNemar’s test was significant at the individual level (p = < 0.001) and herd level (p= 0.0027) 
(Table 1). The percentage of farms with a within-herd prevalence ranging from 1% to 50%, from 
51% to 70%, and from 71% to 100% was 58.2%, 10.98%, and 18.68% respectively (Figure 1).  
The proportion of positive animals evaluated by state is shown in Table 2. The herd prevalence 
with the three geographical regions varied from 69.32% to 83.3% (Figure 3). The geographical 
distribution of sows herds showed that 14 of the 18 (77.7%) U.S. states included in this study 
present at least one SVA seropositive premise (Figure 5). No seropositive farms were detected in 
Idaho, Texas, Wisconsin or Wyoming. The highest prevalence of SVA seropositive adult pigs, 
with more than 60% positive samples from the total evaluated was detected in Nebraska, and 
Missouri (Figure 5). 
Discussion 
SVA has been linked to sporadic cases of swine idiopathic vesicular disease (IVD) for over 
30 years in the United States (4). However, since 2015 the incidence of IVD and ETNL associated 
with the presence of SVA has increased (5, 6). Previous individual reports have described only 
clinical outbreaks of SVA; however, there is no information available regarding the distribution 
and prevalence of SVA in the U.S. 
In the present study, the moderate overall frequency of SVA seropositive grower-finisher 
pigs detected by a combination of SVA rVP1 ELISA and SVA IFA (12.2%) raises the possibility 
that animals are being exposed during grower and finisher stages. In this study, we evaluated a 
broad age range of animals, varying from six weeks old to market weight (on average, 24 weeks 
old). Previous studies have demonstrated that colostral antibodies decline rapidly and are almost 
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undetectable by six weeks of age in piglets born from seropositive but nonclinically affected sows 
(16). Although, we evaluated pigs at six weeks of age and older, the presence of colostral 
antibodies in the youngest pigs evaluated in this study cannot be completely ruled out. 
Furthermore, while all serum samples evaluated were collected from clinically negative sow farms, 
the overall prevalence in reproductive animals, based on results obtained by a combination of both 
tests was 34.0%, indicating that SVA is also circulating in reproductive herds. In a previous study, 
we demonstrated that both clinically and non-clinically affected animals, in a SVA positive farms 
showed the same antibody kinetic i.e., time of detection, duration of the detection, and magnitude 
of the antibody response regardless clinical status (Gimenez-Lirola et al. 2016). In the same study 
performed in a small cohort of neonatal pigs, we observed that animals farrowed from seropositive 
sows can clear the virus within 6 weeks of age and did not present clinical disease (16). Although 
there is no definitive information regarding the potential role of lactogenic immunity against SVA 
associated disease in neonates, these results could have potential implications in reproductive herds 
during the introduction of non-immune/naïve gilt in to general population. The overall prevalence 
rate detected at individual level in sows and grower-finishers showed significant differences 
between both tests used in this study (grower-finishers: 8.7% SVA rVP1 ELISA vs 5.7% SVA 
IFA; sows: 26.2% SVA rVP1 ELISA vs 15.9% SVA IFA). Although, both tests showed a high 
and similar specificity (>98%), estimates of SVA seroprevalence may be influenced by antibody 
specificity and the serologic method used. Thus, the differences in detection rate between SVA 
rVP1 ELISA and SVA IFA could associated not only with the performance of these two tests but 
also with the biological response/variation between individuals evaluated in this cross-sectional 
study. 
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A seroprevalence study  carried out in Brazil indicated that SVA was not circulating in this 
country before 2014 (2007–2013); nevertheless, SVA was circulating between 2014 and 2016 with 
an overall seroprevalence of 36.4%, including  clinically and nonclinically affected animals (28). 
By contrast, our study evaluated the seroprevalence strictly in nonclinically affected herds; 
therefore, the difference in the overall prevalence reported in our study and the prevalence reported 
in Brazil could be due to differences in the clinical status of the animals evaluated. Further 
limitations of the study by Saporiti et al. (28) were the number of samples evaluated (n = 594) and 
the use of virus neutralization, which is more appropriate to assessing protection compared to the 
detection of isotype (e.g., IgG) specific antibodies to evaluating SVA seroprevalence. Although it 
may be reasonable to assume that an individual who is seronegative according to ELISA and IFA 
likely does not have neutralizing antibodies, no assumptions can be made about the levels of 
neutralizing antibodies in individuals who are seropositive according to ELISA and IFA.  
Regarding the herd prevalence, in this study, 42.7% of the grower-finisher pig farms 
evaluated were seropositive, but the within-herd prevalence was variable, which may indicate a 
variable infectious pressure during the grower-finisher stage. Thus, only a low percentage of 
positive farms (1.8%) exhibited a high within-herd seroprevalence (> 70% seropositive animals), 
and more than 50% of the farms exhibited a low seroprevalence varying from 1% to 50% 
seropositive animals. Because no risk factors such as pig density, AIAO/continuous flow, animal 
movements, and disinfection programs were evaluated in this study, predisposing factors 
associated with this low–moderate prevalence require further investigation. Here, we demonstrated 
that SVA is highly prevalent in sow herds in the absence of SVA clinical signs. The frequency of 
positive sow farms was 75.8%; while the herd prevalence was high, the within-herd prevalence 
remained low (< 20%) in a high frequency of farms (Figure 1). In a  previous longitudinal study, 
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we demonstrated detectable levels of IgG antibodies in sows from an endemic SVA infected farm 
for a period of six weeks after first detection of the virus by qPCR, regardless of the presence of 
clinical signs (16). It is also noteworthy that herd detection rate varied between serological 
techniques methods used in this study. While, there is not a real consensus regarding the number 
of seropositive animals to define a positive farm, due to the nature of this study and based on 
parallel testing used to determine the individual overall prevalence and the within-herd prevalence, 
we decided to set a stringent cut-off of two positive animals to define a positive farm. Thus, 
observed variation in the herd detection rate by individual testing versus parallel testing could also 
be associated with the low within-herd prevalence observed in multiple farms. 
Numerous field and experimental studies have shown differences in the dynamic of the 
humoral response against different SVA structural proteins in response to SVA infection (29, 30). 
In this study, VP1 protein was selected as the target antigen for ELISA because it is highly 
conserved (95.8% to 100% amino acid identity) within genus Senecavirus but highly variable, with 
a low percentage (< 30%) of homology in its amino acid sequence with other members of the 
family Picornaviridae (e.g., Cardiovirus). Moreover, it has been reported that VP1 elicits an 
antibody response that allows differentiation among picornaviruses (Kleid et al., 1981). 
Experimental and field studies have shown that IgG against VP1 appear within 7–11 days post 
infection/clinical outbreak and are detectable for at least 6–7 weeks thereafter (16, 24, 27). The 
use of IFA to detect SVA IgG antibody has been widely described. SVA IFA IgG antibody has 
been reported from 10 dpi up to 40 dpi (19, 23, 25). To overcome potential differences in test 
performance due to (1) differences in the dynamic/affinity of the antibody response after natural 
infection, (2) differences in assay platforms or antigen display, (3) differences in target antigens, 
41 
 
and (4) differences in diagnostic specificity, we decided to include two different immunoassay 
methods for IgG antibody detection methods (SVA rVP1 ELISA and SVA IFA).  
A previous study showed a high percentage of agreement (93.7%) between cELISA and 
IFA at the individual diagnostic level (23). In this study, we observed a fair agreement between 
SVA rVP1 ELISA and SVA IFA at the individual diagnostic level (Table 1). However, significant 
differences in test agreement was observed between both techniques at individual level and herd 
level. The proportion of individual animals detected concomitantly by both techniques was lower 
than the proportion of animals detected by a single technique (Table 1). In a cross-sectional study 
like this one, the dynamic of antibody response, time of exposure, infectious exposure dose, and 
immune status of the host are not taken in consideration. Those extrinsic factors, among others, 
bear no relation to test performance. but could also contribute to the observed differences in 
detection rate between both techniques. Even though we set a stringent cutoff of two positive 
animals to determine a positive farm, both tests showed a fair and moderate agreement for sows 
and grower-finisher herd diagnosis, respectively. Although there was significant difference in the 
proportion of farms detected by the SVA rVP1 ELISA vs. the SVA IFA, the combination of both 
techniques greatly improved the SVA antibody detection in sows and grower-finisher herds. 
Clearly, these two different techniques detected different SVA seropositive farms; therefore, the 
additive effect of parallel testing improved the herd detection rate. In addition, the use of parallel 
testing not only has an impact in the farm detection rate but more importantly, it would help to 
determine the within-herd prevalence. In non-clinically affected farms, the detection of individual 
seropositive animals, which seems to be quite frequent, would help to target individual animals for 
partial or complete eradication programs or prevent movement of seropositive animals that could 
be a potential risk when introduced in naïve populations.  
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Conclusion 
In summary, we established baseline data for the prevalence of SVA in major swine 
producing states in U.S. swine herds. In total, 3654 serum samples from 219 farms from 18 swine 
production states throughout the U.S. were evaluated for the presence of SVA antibodies. SVA 
antibody detection by SA rVP1 ELISA or SVA IFA provided strong evidence of the exposure and 
immune response against SVA in sows and grower-finisher pigs in the major swine producing-
states in the U.S. To date, this is the most comprehensive survey of swine exposure to SVA in the 
U.S. swine sow herds and grower-finisher population. Overall, the results obtained in this study 
showed that SVA is widely distributed and circulating subclinically in the major swine producing 
states in the U.S. swine population. 
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Figure 1: Within-herd seroprevalence distribution. White bars represent the frequency of 
grower-finisher farms (n =131) with different levels of within-herd seroprevalence. Black bars 
represent the frequency of sow farms (n =91) with different levels of within-herd seroprevalence. 
Only the results of herds with at least one positive were displayed. 
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Figure 2: Geographic distribution of grower-finisher seropositive herds by geographical 
region. The map represents the percentage of grower-finisher farms detected by geographical 
regions. Region 1: (North Dakota (ND), South Dakota (SD), Nebraska (NE), Minnesota (MN), 
Iowa (IA), Wisconsin (WI), Illinois (IL); Region 2: Michigan (MI), Indiana (IN), Ohio (OH), 
Pennsylvania (PA); Region 3: Colorado (CO), Kansas (KS), Missouri (MO), Texas (TX), North 
Caroline (NC). The table represent the total number and percentage of positive farms detected by 
region with the 95% CI (confidence interval). 
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Figure 3: Geographic distribution of sow seropositive herds by geographical region. The map 
represents the percentage of sow farms detected geographical regions. Region 1: (North Dakota 
(ND), South Dakota (SD), Nebraska (NE), Minnesota (MN), Iowa (IA), Wisconsin (WI), Illinois 
(IL); Region 2: Michigan (MI), Indiana (IN), Ohio (OH), Pennsylvania (PA); Region 3: Wyoming 
(WY), Kansas (KS), Missouri (MO), Texas (TX), Oklahoma (OK), North Caroline (NC), Idaho 
(ID). The table represent the total number and percentage of positive farms detected by region with 
the 95% CI (confidence interval). 
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Figure 4: Geographic distribution of grower-finisher seropositive herds by state. The map 
represents the percentage of grower-finisher farms detected by states. The table represent the total 
number and percentage of positive farms detected by stat with the 95% CI (confidence interval). 
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Figure 5: Geographic distribution of sow seropositive herds by state. The map represents the 
percentage of sow farms detected by states. The table represent the total number and percentage 
of positive farms detected by stat with the 95% CI (confidence interval). 
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Tables 
Table 1 ELISA-IFA Test Agreement 
  ELISA-IFA test agreement 
  ELISA 
negative 
ELISA 
positive 
Kappa statistic  
(SE; 95% CI) 
McNemar Test† 
Sow individuals      
 IFA, negative 1591 448 
0.21 (0.02; 0.17-0.25) < 0.001 
 IFA, positive 198 191 
Grower-Finisher 
individuals 
     
 IFA, negative 3103 238 
0.23 (0.02; 0.17-0.28) < 0.001 
 IFA, positive 130 72 
Sow farms      
 IFA, negative 11 20 
0.31 (0.1; 0.11-0.51) 0.0027 
 IFA, positive 5 55 
Grower-Finisher 
farms 
   
  
 IFA, negative 58 24 
0.49 (0.07; 0.34-0.63)  0.009 
 IFA, positive 9 40 
Cohen kappa coefficient: poor, <0.20; fair, 0.20–0.39; moderate, 0.40–0.59; good, 0.60–0.79; 
and excellent, ≥0.80. † Values <0.05 were considered significant. 
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Table 2 Pig Distribution by State  
Table 2; 95 % CI confidence interval; n/e not evaluate; n/a: not available  
 
 
 
 
Percentage of positive grower-fishier pigs by 
state 
Percentage of positive sows by state Pig 
inventory 
by state 
State Total samples 
evaluated (n) 
Percentage of 
positive  (%) 
95% CI Total samples 
evaluated (n) 
Percentage of 
positive  (%) 
95% CI (1,000 head) 
Iowa  677 16.2 13.42-18.98 295 34.2 28.79-39.61 22,800 
North Carolina  199 6.03 2.72-9.34 320 16.2 12.21-20.29 9,000 
Minnesota 80 8.7 2.52-14.88 101 14.8 7.92-21.78 8,500 
Illinois 703 6.8 4.94-8.66 415 47.9 43.14-52.76 5,350 
Indiana 247 16.6 12.0-21.28 61 42.6 30.19-55.01 4,050 
Nebraska 165 22.4 16.04-28.76 110 73.3 65.1-81.62 3,600 
Missouri  75 4 0.0-8.86 185 61.1 54.05-68.11 3,400 
Ohio 396 6.1 3.74-8.46 186 35.5 28.6-42.36 2,950 
Oklahoma n/a n/a n/a 55 58.2 45.16-71.24 2,220 
Kansas 370 7.6 4.9-10.3 25 20 4.32-35.68 2,110 
South Dakota 25 76 59.26-92.74 89 12.3 5.51-19.19 1,526 
Pennsylvania  381 18.6 14.69-22.51 277 34.6 29.0-40.2 1,250 
Michigan  60 3.3 0.0-7.82 145 12.4 7.04-17.76 1,190 
Texas 30 0 n/a 30 3.33 0-9.75 1,040 
Colorado 109 29.3 20.76-37.84 n/e n/e n/e 750 
Wisconsin 49 6.1 0.0-13.54 28 3.57 0-10.4 350 
North Dakota  88 31.8 22.07-41.53 60 28.3 16.93-39.73 147 
Wyoming n/a n/a n/a 30 0 n/a 90 
Idaho n/e n/e n/e 21 0 n/a n/a 
Total 3654 12.7 11.62-13.78 2433 34.04 32.16- 35.92  
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CHAPTER 3. DEVELOPMENT OF A MOUSE MODEL FOR SENECAVIRUS 
PATHOGENESIS AND TRANSMISSION 
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Abstract 
Senecavirus A (SVA) is a RNA virus in the family Picornaviridae. SVA has recently been 
identified as a causative agent of vesicular lesions and increased neonate mortality in swine. SVA 
neutralizing antibodies and nucleic acid have been reported in mouse samples from swine 
facilities. The objective of this study was to evaluate transmission of SVA in experimentally 
infected mice. To evaluate mice strain susceptibility, ten 8-week-old mice (BALB/C, SWISS, 
SJL/J, and C57BL/6) and 4-week-old mice (SCID) were inoculated subcutaneously (SC) with 100 
µL of SVA at 109 TCID50/mL. Transmission was evaluated by adding 1 mock inoculated mouse 
per cage for the duration of the study (14 dpi). Intraperitoneal (IP), intranasal (IN), and SC routes 
of inoculation were assessed for 10 BALB/C mice per group and evaluated for 28 dpi. In all 
experiments, mice were monitored every 6 hours for the first 72 hours post-infection and daily 
thereafter. Body weight, clinical signs and virus shedding in feces were collected daily from 
individual mice. Blood and a select set of tissues (brain, heart, lung, liver, spleen, kidney, and 
intestine) were collected for viral detection by PCR, histopathology, and in situ hybridization. No 
differences in clinical signs were observed among strain and route. Except for SCID and control 
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animals, all infected and sentinel mice developed SVA IgG response. Viral RNA was detected in 
all tissues from directly inoculated mice at 14 dpi, regardless of strain. Viral shedding in feces was 
observed in infected mice. Sentinel animals had inconsistent shedding between 5 to 10 dpi. In mice 
inoculated by SC and IP route viremia was detected as early as 3 dpi,. SVA caused subclinical 
infection in mice and induce seroconversion. Viral shedding in sentinel mice supports previous 
observations that mice could be a reservoir or vector of SVA in swine herds. 
 
Key Words: Senecavirus, SVA, transmission, mice, shedding 
 
Introduction 
Senecavirus A (SVA) is a nonenveloped, single-stranded RNA virus belonging to the genus 
Senecavirus in the family Picornaviridae (1). SVA is composed of four structural proteins (VP1-
4) and seven nonstructural proteins (2). It was discovered as a contaminant of PER.C6 cell culture 
in 2002 and has been associated with swine idiopathic vesicular disease (IVD) (2, 3). SVA has 
been described in the U.S. swine population for over 30 years (4). In 2015, it was associated with 
outbreaks of IVD and epidemic transient neonatal losses (ETNL) (5, 6). Such outbreaks were then 
described in many countries including Brazil (7, 8), China (9, 10), Colombia (11), and Thailand 
(12). 
 Mouse models had been used to study multiple viruses of the family Picornaviridae, 
including closely related foot and mouth disease virus (FMDV) (13-15). Rodents are near 
ubiquitous on swine farms and are a biosecurity concern, as they have also been shown to act as a 
reservoir for encephalomyocarditis virus (16). Research in FMDV epidemiology has determined 
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that mice are susceptible to the virus under experimental conditions, though they are not involved 
in disease epidemiology (17). Mice were first used in FMDV studies beginning in 1951, where 
unweaned mice were inoculated by intraperitoneal route (18). This route has since been used in a 
variety of studies, inducing clinical signs including muscular paralysis when infected before 3-4 
weeks of age. Mice do not develop vesicular lesions following infection with FMDV (19). Adult 
mice show no signs of disease, but some strains are capable of undergoing subclinical infection: 
CH3, Swiss, BALB/C, SJL, and nude strains. Infected animals experienced a transient viremia and 
developed neutralizing antibodies (20, 21). Some serotypes and variants proved lethal for adult 
C57BL/6 and BALB/C mice. Additional studies have described inoculation through intramuscular 
(22) and subcutaneous foot pad (21), as well as the original intraperitoneal route. 
Swine appear to be the only natural host for SVA; however, retrospective studies 
demonstrated the presence of SVA neutralizing antibodies in mice and cattle. Recent studies 
showed that environmental samples collected from SVA outbreak sites yielded detection of SVA 
nucleic acid in both the feces and small intestines of mice sampled on site. Further evaluation 
confirmed the presence of live infective virus by virus isolation (23). 
 Mice have also been used in many in vivo models examining the oncolytic properties of 
SVA in attempt to develop a therapeutic agent for humans. Neutralizing antibody to the virus has 
been found in mice used in these studies (24). Liu et al. used an orthotopic xenograft Rag2 severe 
combined immunodeficient (SCID) mice for a model of pediatric glioblastoma multiforme. For 
this study, mice were inoculated intravenously with 5 x 1012 viral particles per kg body weight of 
SVV-001. The only clinical signs observed in this study were related to the neurologic effects of 
the tumor (25). Additional studies have used Rag2 SCID mice for medulloblastoma (26) and Y79 
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retinoblastoma models (27). In these experiments, SVV-001 was successful in reducing tumors, 
but did not directly elicit recorded clinical signs of illness. 
The objective of this study was to explore SVA transmission and clinical outcomes in an 
experimental mouse model. Given the success of previous studies using mice and their prevalence 
in livestock facilities, they have potential to act as a model for SVA infection, transmission, and 
pathogenesis. 
Materials and Methods 
Determination of mouse strain susceptibility - Study design 
Three male and three female 8-week-old mice from BALB/C, C57BL/6, SJL/J, and Swiss 
strains, as well as three male and three female 5-week-old SCID mice were used to determine mice 
strain susceptibility against SVA infection. Mice were allowed one week of acclimatization in the 
laboratory animal facility at Iowa State University. At the time of arrival, mice were weighed and 
ears notched for identification. Mice were housed by strain and sex in groups of three and received 
standard mouse feed and water ad libitum. Wood shaving bedding and standard enrichment was 
provided and not changed during the duration of the study.  
Each mouse was inoculated subcutaneously in the rear left footpad (RLFP) with 100 µL of 
SVA at 109 TCID50/mL in RPMI-1640 media. For direct contact transmission evaluation, one 
female from each strain was designated the sentinel animal and was sham inoculated with RPMI-
1640 media (Figure 1). Mice were monitored every four hours for the first 72 hours, then once 
daily for the duration of the fourteen-day study. Body weight and clinical signs were evaluated 
daily. Clinical signs included difficulty breathing, cutaneous rash, and lameness. Viral shedding 
in feces was evaluated after feces collection from each individual animal once daily. At 14 dpi, 
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mice were administered 65 mg/kg ketamine with 4mg/kg xylazine via intraperitoneal route for 
anesthesia prior to cardiac puncture for blood collection. Without regaining consciousness, mice 
were then euthanized using carbon dioxide, followed by cervical dislocation. A necropsy was 
performed, and a full set of tissues including heart, lungs, spleen, liver, intestine, kidney, and brain 
were collected. Fresh tissues were stored at -80°C for further SVA PCR evaluation. Tissues were 
also collected and stored in 10% neutral buffered formalin for histopathological examination and 
viral detection by in situ hybridization.  
Determination of mouse infectious route - Study design 
In order to determine the most efficient infectious route, mice were inoculated by several 
methods. Ten BALB/c mice were inoculated either subcutaneously in the RLFP, intraperitoneally 
(IP), or intranasally (IN) with 100 µL of 109 TCID50/mL SVA. Mice were clinically monitored as 
previously described for the mice strain susceptibility study, every 6 h for the first 72 h and daily 
thereafter for 28 dpi. Feces and weight measurements were collected daily. Blood was collected 
from the submandibular vein at 0, 3, 5, 7, 10, 14, 17, 21, and 28 dpi. Each mouse was manually 
restrained and the vein punctured using 23G needle. A maximum of 100 µL of blood was collected 
in EDTA blood capillary tubes and spun at 2000g for 10 minutes to separate serum. After 
venipuncture, pressure was applied with gauze until bleeding ceased. At 28 dpi mice were 
administered 65 mg/kg ketamine with 4mg/kg xylazine via intraperitoneal route for anesthesia 
prior to cardiac puncture for blood collection. Without regaining consciousness, mice were then 
euthanized using carbon dioxide, followed by cervical dislocation. A necropsy was performed for 
macroscopic evaluation and tissue collection. Fresh tissues were stored at -80°C for further SVA 
PCR evaluation. Tissues were also collected and stored in 10% neutral buffered formalin for 
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histopathological examination in viral detection by in situ hybridization. This experiment was run 
in two biological duplicates. 
SVA antibody detection in mice 
The presence of specific SVA IgG was evaluated in terminal serum by three serological 
methods including rVP1-ELISA, whole virus ELISA, and indirect immunofluorescence assay 
(IFA) for the mice strain susceptibility study. The IgG antibody dynamic was evaluated by IFA 
for the mouse infectious route susceptibility study.  
A rVP1-ELISA was run as previously described (28) for swine serum. In brief, 96-well 
high binding plates were coated with recombinant VP1 protein at 0.18 µg/mL. One-hundred µL of 
sera diluted 1:50 were added and incubated at 37°C for 1 h. Plates were washed five times with 
phosphate buffered saline containing 0.1% Tween 20 (PBS-T) before 100 µL of horseradish 
peroxidase-conjugated goat anti-mouse IgG (Fc) antibody (Pierce Protein Biology) was added, 
diluted 1:5,000. Peroxidase activity was monitored by adding 100 µL of tetramethylbenzidine-
hydrogen peroxide (TMB) substrate solution for five minutes at room temperature in a darkened 
environment. The reaction was terminated by addition of 100 µL of stop solution. Finally, optical 
density was measured at 450nm using an automated plate reader (BioTek ELx800, Winooski, VT, 
USA) operated with commercial software. Positive control sera was SVA polyclonal antibody 
generated in a mouse. Negative control sera was collected from an uninfected laboratory mouse.  
Samples were also tested by SVA whole virus ELISA. SVA was clarified and centrifuged 
for 15 minutes at 4,000 rpm and 4°C. Supernatant was then spun for two hours 28,000 rpm and 
4°C. The resulting pellet was resuspended in PBS. One-hundred µL of viral particles were diluted 
1:400 in PBS and coated onto 96-well high binding microtiter plates (Thermo Fisher Scientific). 
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Whole virus ELISA plates were incubated for 16 hours at 4°C. Plates were washed five times with 
PBST and blocked with 1% bovine serum albumin solution (Jackson ImmunoResearch Inc.) for 
two hours at 25°C. Samples were diluted 1:50 and a total 100 µL per well were then incubated for 
one hour at 37°C followed by five washes with PBST. Reaction was revealed by adding 1:10,000 
dilution of peroxidase conjugated goat anti-mouse IgG (Fc) antibody (Pierce Protein Biology) for 
30 minutes at 37°C. Addition of 100 µL per well of TMB allowed for visualization of the 
peroxidase reaction. Reactions were stopped with 100uL Nova-stop after 5 minutes. Optical 
density was read at 450 nm. 
Finally, an indirect immunofluorescence assay (IFA) was performed on all samples from 
NCI-H1299 cells were grown in 96-well plates. Each well was inoculated with 1x103 TCID50/mL 
SVA. After 24 hours, cells were fixed with 200 µL cold 90% acetone for 10 minutes at 4°C. Cells 
were washed with 200 µL PBS, then incubated with 50 µL two-fold serial dilution mouse serum 
at 37°C for one hour. Wells were washed three times with 200 µL PBS and incubated with 50 µL 
of FITC labeled anti-mouse IgG (KPL Scientific, Montreal, Quebec, CAN), diluted 1:100, at 37°C 
for 30 minutes. Plates were washed three times with PBS and examined under a fluorescence 
microscope. 
SVA detection in serum, feces and tissue by RT-qPCR 
The presence of SVA was evaluated in feces, serum, and tissue samples using RT-qPCR 
by Tetracore Inc. Two fecal pellets were added to 0.5 mL PBS and vortex agitated for 20 seconds. 
Five grams of tissue, when possible, were suspended in 1:10 weight/volume ratio in PBS, 
macerated for 10-15 min using a Stomacher 80 lab blender (Seward Laboratory Systems Inc., 
Bohemia, NY), and centrifuged at 1500 × g for 10 min. The obtained tissue homogenate 
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supernatants were aliquoted and stored at -80C until usage. All samples were manually extracted 
using the QIAamp Viral RNA Mini Kit (Qiagen, Germantown, MD, USA) following the 
manufacturer’s recommendations. To control the integrity of the extraction and PCR reaction, 6 
µL of 800 copies per µL of internal control RNA from Tetracore, Inc. was added to the lysis buffer. 
The viral RNA was eluted in 90 µL of elution buffer. Seven µL of each extracted sample was 
tested using 18 µL of real-time RT-PCR EZ-SVA reagents from Tetracore, Inc. This reagent 
targeted the conserved sequence of the 3D region of the SVA genome. Real-time RT-PCR was 
performed on an ABI 7500 Fast instrument (Life Technologies) with the following conditions in 
standard mode: 1 cycle of 48°C for 15 minutes, 1 cycle of 95°C for 2 minutes, then 45 cycles of 
95°C for 5 seconds and 60°C for 40 seconds. To analyze PCR data, the baseline was set to 
automatic. Threshold settings were set to the maximum of the positive control for SVA and internal 
control. For a negative result to be considered valid, the internal control for the sample required a 
Ct value less than 40. 
Histological evaluation and SVA detection in tissue by RNAScope in situ hybridization  
All tissues samples collected during necropsy were fixed in 10% buffered formalin, 
processed for routine histopathologic examination, and stained with hematoxylin and eosin. In situ 
hybridization (ISH) was performed through the RNAScope platform (Advanced Cell Diagnostics, 
Inc., CA). The test targeted the specific reverse complimentary nucleotide sequence of the 301-
345 region of the VP1 gene (GenBank: EU271758.1). Positive signals correlated with 
metabolically active SVA characterized by the mRNA coding for the VP1 protein. Unstained 
paraffin tissue sections were processed as previously described (29). These sections were 
deparaffinized and treated with hydrogen peroxide for 10 minutes. The slides were hybridized 
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using a hybridization buffer and sequence amplifiers were added. Red colorimetric staining 
detected the SVA hybridization signal and counterstaining occurred with hematoxylin. 
 Statistical Analysis 
Group sizes were established using multiple power analyses using ANOVA and ANCOVA 
models. GraphPad Prism 7.03 software was used to visualize mean and standard deviation of 
serologic tests at each time point. For serological and virus detection, an unpaired t test was run to 
analyze each group against the negative control, using the Holm-Sidak method to correct for 
multiple comparisons and using a p-value of 0.05 to assess significance. 
Results 
Senecavirus can cause subclinical infection in different laboratory mouse strains  
Throughout the duration of the 14-day study, no vesicular lesions, systemic signs of illness, 
or significant loss in body weight were observed among the evaluated strains. Clinically, only 
BALB/c mice developed mild clinical signs including a rough coat, poor body condition, and a 
slight decrease in body weight in the three days immediately following infection. However, these 
changes were not significant compared with other mouse strains or sentinel mice. All infected 
animals, except SCID mice, developed a SVA IgG antibody response detected by SVA-rVP1 and 
whole virus indirect ELISA, and IFA (Figure 2A-C). Sentinel mice, housed with infected animals, 
did not develop a humoral response by 14 dpi. Different levels of viral shedding in feces were 
observed in infected mice throughout the study. At 24 hours post inoculation, 100% of the SWISS, 
BALB/C and SJL mice and 80% of the SCID shed virus in feces. Interestingly, 80% of the sentinel 
mice housed with subcutaneously infected mice shed virus at 4 dpi. Viral shedding in feces was 
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still detectable in a small subset (approximately 20%) of infected and sentinel mice at the end of 
the study (Figure 3). Nucleic acid was detected at 14 dpi in all tissues and all inoculated mouse 
strains (Figure 4). SVA nucleic acid was not detected in tissues of sentinel mice by RT-qPCR, 
except two mice with a positive detection in the kidney (Table 1).  
During histological evaluation, no significant changes were observed among different 
strains of infected or sentinel mice. Viral replication in tissue was evaluated by RNAScope in situ 
hybridization. The presence of viral replication was only observed in the small and large intestines 
of infected mice, mainly in in enterocytes and lymphocytes of the lamina propria. Positive signal 
was detected in the small and large intestine of BALB/C (3/3), C57BL (2/2), and SJL mice (2/2). 
SCID and SWISS mice showed positive signal in (1/2) of both small and large intestinal samples 
(Figure 5). No positive hybridization signal was observed in negative control mice.  
Subcutaneous and intraperitoneal inoculation resulted in subclinical infection 
No significant clinical signs or weight loss were observed throughout the duration of the 
28-day study regardless of the inoculation route. No vesicular lesions or systemic signs of illness 
were observed among the different inoculation route groups compared with the negative controls.  
The inoculation route appeared to have an important effect on SVA humoral response. 
Mice inoculated by subcutaneous or intraperitoneal route developed a strong IgG antibody 
response detected by IFA at 7 and 10 dpi respectively. Antibody response increased gradually 
throughout the study with the highest IgG concentration observed by 17 dpi. No significant 
differences in fluorescence intensity level (IgG levels) were observed between IN and control 
groups (Figure 6).  
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A transient viremia was observed in a high percentage of mice inoculated by SC and IP 
route. Viral RNA was detectable at 3 dpi in 60% of SC and IP inoculated animals, with a gradual 
decrease in the number of viremic animals in both groups as the study progressed. At 21 dpi, none 
of the SC mice and only one IP mouse had a detectable viremia. However, an increase in the 
percentage of viremic animals was observed at 28 dpi, particularly in the IP group. A small subset 
of mice showed moderate viremia at 3 and 28 dpi in the IN group. Negative control remained 
negative throughout the study (Figure 7).  
Viral shedding was observed in animals inoculated by all three infectious routes. SVA 
nucleic acid was detected in the feces of 100% of the SC and IN mice, and 50% of the IP inoculated 
animals 1 dpi. Feces from negative control animals remained negative throughout the study (Figure 
8). 
Viral RNA was detected in multiple tissues of the SC, IP, and IN groups. Although no 
clinical signs or significant gross lesions were observed, animals in the IP group showed the 
highest percentage of detection among the different inoculation routes in the heart, lung, liver, 
spleen, kidney, and intestine (Table 2). In addition, the IP group also presented significantly higher 
Ct values in the heart, liver, kidney, and intestine (Figure 9). SVA nucleic acid was also detected 
at lower percentage in the SC groups, with a higher percentage of detection in liver and spleen 
(Table 2). The liver and spleen also contained the highest observables Ct values among all tissues 
evaluated for this group (Figure 8). In the IN group, SVA nucleic acid was only detected in heart, 
and liver with significant lower Ct (Figure 9) values and lower percentage (Table 2) of positive 
animals compared with IP or SC groups. Interestingly, brains were negative at 28 dpi regardless 
of the infectious route (Figure 9, Table 2).  
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Discussion 
 Murine models have been described for the study of many members of the family 
Picornaviridae (13, 14). These models have helped develop understanding and dissect the 
pathogenesis of FMDV and Cardioviruses. In addition, mouse models have been used to lead all 
advances associated with SVA oncolytic therapy for human cancer, including pediatric 
glioblastoma multiforme (25), medulloblastoma (26), and retinoblastoma (27). 
Previous studies with foot and mouth disease virus have shown that mouse models can 
reproduce vesicular disease and mortality. However, these clinical outcomes appear to be 
dependent on mouse strain and age (19). Intraperitoneal inoculation of lactating mice caused 
development of epithelial ballooning and degeneration of keratinocytes in the footpad. While, 
different adult mouse strains including CH3, Swiss, BALB/C, and SJL developed subclinical 
infection after intraperitoneal inoculation with FMDV (20, 21). In this study, five different mouse 
strains including BALB/C, C57BL/6, SJL/J, Swiss, and SCID were inoculated subcutaneously 
with SVA. All mouse strains in this study had detectable viremia by 14 dpi, in addition to viral 
detection in multiple tissues. No significant difference in SVA detection rate were observed among 
strains. Finally, all mouse strains except for SCID mice developed a strong humoral response by 
14 dpi. However, despite this strong evidence of viral replication and systemic spreading of the 
virus we did not observed lethality or significant clinical signs of systemic illness in any of the 
evaluated strains. In addition, gross and histological evaluation showed that SVA does not induce 
cutaneous vesicles or significant lesions in other tissues after 14 dpi. Based on these results, we 
suggest that SVA can produce subclinical infection in multiple strains of laboratory mice by 
subcutaneous inoculation.  
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Since no difference in mouse strain susceptibility was observed in our first study, we aimed 
to determine if changes in infectious route could affect SVA infectivity in BALB/C mice. Previous 
studies with FMDV explored different infectious routes in adult mice. Mice are more susceptible 
to SC and IP infection against FMDV, resulting in neurological disease or increased mortality (21). 
Although no clinical differences were observed among the different infectious routes in this study, 
IP and SC inoculation appeared to cause subclinical infection. In both groups there was acute 
viremia and viral shedding in feces detected within three dpi. Unlike pigs, fighting and grooming 
play a large role in the spread of viral disease in mice (30). Our results suggest that SC and IP route 
better mimic the natural exposures that would occur through biting, grooming, and physical contact 
than IN route. While mucosal transmission may play a role in mouse infection, IN inoculation 
without disruption of mucous membranes was not sufficient in causing infection. This ecological 
information may be crucial in understanding why direct contact between mice is important for 
viral spread. 
Due to the lack of vesicular lesions or lethality associated with SVA infection in different 
mouse strains and different infectious routes under the experimental conditions used for these 
studies, a mouse model does not seem to be an appropriate model to study vesicular disease 
induced by SVA. Although experimental SVA inoculation can produce vesicular disease in 
grower-finisher pigs, clinical evaluation of sows and their offspring during a break of SVA 
associated IVD showed that both can be subclinically infected with observable viremia, viral 
shedding in feces and oral fluids, and acute seroconversion (31). Similar results were observed in 
this study for multiple mouse strains, and by SC and IP inoculation. The main co-factors necessary 
to trigger SVA associated vesicular disease in naturally infected pigs are still unknown. Therefore, 
further studies to evaluate potential co-factors triggering clinical disease in mice would be 
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necessary. Despite the lack of vesicular disease, mice could still be an important model to 
understand the subclinical presentation of SVA in pigs.   
The viremia detected in these studies resembles a pattern of viremia observed in 
experimentally infected pigs, with an acute onset observed approximately 3 dpi and a duration 
varying from 10-15 dpi (32). The detection of SVA in multiple tissues by RT-qPCR could be due 
to 1) active tissue replication or 2) extended viremia. However, virus replication was only detected 
by RNAScope in situ hybridization in small intestine and large intestine. These results may 
indicate that nucleic acid detection in other tissues could be the result of viremia without active 
viral replication. Viral cell tropism during in vivo studies performed in pigs suggested that virus 
replicated in dendritic cell and macrophages. Antigen detection by IHC showed viral activity in 
enterocytes of neonatal pigs after an ETNL break (33). Our mouse model showed subclinical 
infection with persistent viremia and viral shedding in feces, similar to observations in neonatal 
swine during herd breaks of IVD.  
Swine appear to be the only natural host for SVA; however, retrospective studies 
demonstrated the presence of SVA neutralizing antibodies in mice and cattle (24). In the current 
study, we evaluated the presence and dynamic of the IgG antibody response in different mouse 
strains and different infectious routes. The production of IgG antibody after SVA infection in mice 
is acute, with antibodies levels detectable after 7 dpi in all inoculated strains. This rapid 
development of specific humoral response is consistent with results observed in experimentally 
inoculated pigs. Although the antibody neutralizing activity was not evaluated in this study, 
previous experiments in swine demonstrated that neutralizing activity is likely related to the 
presence of IgM (34). The IgG antibody response was not affected by strain. All mouse strains 
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used in this study, expect SCID mice, showed a strong humoral response by 14 dpi. Interestingly, 
sentinel mice showed viral shedding in feces and presence of nucleic acid in the kidney, which 
may indicate lateral infection. However, no specific antibody response was observed. In addition, 
in our infectious route study, animals inoculated IN did not showed a specific IgG response. A low 
infectious dose due to oral infection in sentinel mice and infectious route could be factors 
associated with the humoral response in experimentally infected mice.  
One of the important factors associated with SVA epidemiology and ecology is its 
persistence in the environment and potential viral vectors or reservoirs on pig farms. Previous 
studies demonstrated the presence of viable virus in environmental samples surrounding swine 
herds after an IVD break. These studies also demonstrated that SVA can be re-isolated from mouse 
feces and intestinal content (23). In this study, viral shedding in feces was observed in all animals, 
regardless of strain or infectious route. Viral shedding seemed to be transient and only lasting for 
two weeks in the mouse strain study; however, due to the experimental design, animals housed in 
the same environment for longer periods of time could be exposed to reinfection by oral exposure, 
as was observed in animals inoculated IP. Lateral transmission and persistence in the environment 
are additional factors to consider during eradication or preventive program in swine herds. 
Transmission among mice could perpetuate SVA in the environment without clinical evidence of 
mouse infection. A high percentage of sentinel mice showed viral shedding after three day of 
cohabitation with experimentally infected mice. Although they remained subclinical, perhaps due 
to the infectious dose or infectious route, they shed virus for approximately 10 days. These results 
demonstrate that mice could act as reservoirs or potential viral sources in the environment.  
In conclusion, mice may act as a reservoir or vector for SVA infection in swine, with 
transmission occurring through fecal shedding, urine, or direct contact. Wild mice are widespread 
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across the United States and ubiquitous in production animal housing. Virus may be transmitted 
mouse to mouse through direct animal or fecal contact, and would allow the virus to travel far 
distances, reaching previously uninfected swine facilities. Should this be the case, increased pest 
management and changes in biosecurity could prevent spread of disease among swine herds.  
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Figure Legends 
 
 
Figure 1- Schematic representation of mouse grouping and housing.  Mice were housed by 
sex in groups of three. One sentinel animal was sham inoculated with RMPI-1640 media and 
housed with two mice inoculated with SVA.  
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Figure 2- Serological response to SVA inoculation. Serological response at 14 days after 
subcutaneous injection with 106 TCID50/mL SVA. Antibodies were measured using IFA (A), 
indirect whole virus (B), and SVA-rVP1 ELISA (C). These figures show mean and standard 
deviation for five mice per strain. Negative control values are the average of one sentinel animal 
from each strain. No significant difference in optical density was observed among the C57BL, 
BALB/C, SJL, and SWISS groups. 
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Figure 3- Fecal shedding. Viral shedding was evaluated by RT-qPCR of feces, collected daily. A 
high percentage of infected animals from all five strains showed fecal shedding beginning 1 dpi, 
with a small subset of animals in each strain shedding by 14 dpi. Sentinel animals displayed 
intermittent shedding between 4 and 9 dpi. 
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Figure 4- SVA detection in tissue from different mouse strains 14 dpi. The presence of SVA 
was detected in all tissues evaluated in all infected strains. Bars represent mean and standard 
deviation of Ct values in five mice per strain. No significant difference in Ct values were observed 
among tissues or subcutaneously infected mouse strain.  
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Figure 5- RNAScope detects viral replication in the small and large intestine. RNAScope in 
situ hybridization detected viral replication enterocites and the lamina propria of the small and 
large intestine of mice from all five strains. No viral replication was observed in sentinel mice. 
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Figure 6- Humoral immune response by inoculation route. Mice inoculated by SC or IP route 
developed a humoral immune response detected by IFA beginning 7-10dpi. IN and negative 
control animals did not demonstrate a humoral immune response throughout the duration of the 
28-day study. 
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Figure 7 - Viremia by inoculation route. Mouse inoculated by SC and IP route experienced a 
transient viremia peaking 3 dpi and gradually decreasing. Viremia was detectable to the end of the 
study, 28 dpi, in animals from both groups. IN experienced a less consistent viremia, with less than 
20% of IN mice positive by PCR only on 3 and 28 dpi. Control animals developed no viremia at 
any time point. 
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Figure 8- SVA fecal shedding by inoculation route. Viral RNA was detected in the feces of 
BALB/C mice inoculated with SVA by SC, IP, and IN route beginning 1 dpi. The highest 
percentage of animals shedding SVA in feces was observed 3 dpi regardless the inoculation route.. 
SVA was not detected after 10 dpi for IP and IN inoculated animals, and after 14 dpi for SC 
animals.  
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Figure 9- SVA positive tissues by inoculation route. The study was terminated at 28 dpi and 
tissues were collected. Using a cut-off of 38, RT-qPCR revealed positive tissues in SC, IP, and IN 
groups. The highest inverse Ct values were found in the IP group of animals, particularly in the 
intestines. Additional positive tissues included heart, lung, liver, spleen, and kidney. No brain 
tissues were positive and control animals had no detectable viral RNA.  
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Tables 
Table 1- PCR distribution among strains and tissues. RT-qPCR was run on tissues collected at 
necropsy. This chart shows the number of positive samples compared to the number of samples 
tested (in parenthesis) for each tissue type. Every infected strain and tissue possessed nucleic acid. 
Sentinel animals did not demonstrate nucleic acid on PCR, with the exception of two kidney 
samples. 
Positive/total (%) 
Strain Brain Heart Lung Liver Spleen Kidney  Intestine 
SCID 1/5 (20) 5/5 (100) 5/5 (100) 5/5 (100) 5/5 (100) 5/5 (100) 5/5 (100) 
C57BL 4/5 (80) 4/5 (80) 4/5 (80) 4/5 (80) 4/5 (80) 5/5 (100) 5/5 (100) 
BALB/C 4/5 (80) 5/5 (100) 5/5 (100) 5/5 (100) 5/5 (100) 5/5 (100) 5/5 (100) 
SJL 3/5 (60) 5/5 (100) 5/5 (100) 5/5 (100) 5/5 (100) 5/5 (100) 5/5 (100) 
SWISS 4/5 (80) 5/5 (100) 5/5 (100) 5/5 (100) 5/5 (100) 5/5 (100) 5/5 (100) 
Sentinel 0/5 (0) 0/5 (0) 0/5 (0) 0/5 (0) 0/5 (0) 2/5 (40) 0/5 (0) 
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Table 2- PCR distribution among routes and tissues. RT-qPCR revealed SVA specific RNA in 
multiple tissues when comparing inoculation routes. IP route resulted in the most positive samples, 
including heart, lung, liver, spleen, kidney, and intestine. The most frequently positive tissue by 
IP route were intestine and liver with 95% of animals PCR positive. SC and IN route also resulted 
in detection of RNA in multiple tissues. However, a lower percentage of animals yielded PCR 
positive tissues. No SVA specific RNA was detected in any control animal tissue or in the brain 
of any tissue. 
Positive/total (%) 
Route Brain Heart Lung  Liver Spleen  Kidney Intestine 
Subcutaneous 0/10  
(0) 
2/20 
(10) 
0/20  
(0) 
15/20 
(75) 
18/20 
(90) 
2/20  
(10) 
9/20  
(45) 
Intraperitoneal 0/10  
(0) 
7/20 
(35) 
15/20 
(75) 
19/20 
(95) 
15/20 
(75) 
6/20  
(30) 
19/20 
(95) 
Intranasal 0/8  
(0) 
2/18 
(11.1) 
8/18 
(44.4) 
2/18 
(11.1) 
1/18 
(5.5) 
0/18  
(0) 
2/18 
(11.1) 
Control (Neg) 0/10  
(0) 
0/17 
(0) 
0/17  
(0) 
0/17 
(0) 
0/17  
(0) 
0/17 
(0) 
0/17  
(0) 
 
  
  
CHAPTER 4. CHARTERIZATION OF THE IMMUNODOMINANT REGIONS OF 
SENECAVIRUS A-VP1 STRUCTUAL PROTEIN BY ELISA EPITOPE MAPPING 
 
 
Elizabeth Houston, Luis Giménez-Lirola, Avanti Sinha, Juan Carlos Mora-Díaz, Nicholas 
Villarino, Pablo Piñeyro 
 
 
Abstract 
Senecavirus A (SVA) is a RNA virus in the family Picornaviridae. The virus has been 
recently detected in swine production systems, causing vesicular disease and neonate mortality. 
The viral capsid is composed of four structural proteins: VP1-VP4. Although the VP1 protein has 
been reported as the most immunogenic proteins in vivo, no information on immunodominant 
regions of the SVA polyprotein is available. The objective of this study was to identify 
immunodominant regions of SVA polyprotein using epitope mapping. The binding effect of SVA 
polyclonal antibody (SVA-pAb), SVA-VP1 monoclonal antibodies (mAb), and SVA positive sera 
from clinically affected animals were characterized using a set of SVA-VP1 derived peptides by 
indirect and blocking ELISAs. Epitope array was based on 18 SVA-VP1 peptides, overlapping 20-
mer and shifted by five amino acids. All VP1-derived peptides yielded significant signal against 
SVA-pAb and VP1-mAb by indirect ELISA. One peptide (aa 1-20) showed significantly higher 
OD on rVP1 and SVA whole virus indirect ELISAs. Peptides spanning aa 1-20, 60-80, 105-125, 
120-140 showed a significant half maximal inhibitory concentration (IC50) on VP1-mAb against 
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rVP1 by blocking ELISA. Although several peptides showed variable binding inhibitory effect of 
SVA-pAb and SVA-positive clinical samples, none of the peptide reach a 50% inhibitory effect. 
These results suggest that the humoral immune response against SVA-VP1 can be defined by a set 
of linear epitopes. Further investigation is warranted to determine if these peptides are indeed 
responsible for neutralizing antibodies against SVA. 
 
Key Words: Senecavirus, VP1, immunogenicity, epitopes, ELISA 
 
Introduction 
Senecavirus A (SVA), formerly known as Seneca Valley Virus, is the only member of the 
genus Senecavirus in the family Picornaviridae. This single-stranded, positive-sense RNA virus 
was originally discovered as a contaminant in PER.C6 culture cells and described retrospectively 
in United States’ swine herds (1-3). Recently, SVA infection has been associated with idiopathic 
vesicular disease. In 2015, outbreaks of vesicular disease and neonatal mortality related to SVA 
were reported in numerous swine producing countries, including the United States (4-7), Brazil 
(8), Colombia, Thailand, China (9), and Vietnam (10). SVA vesicular presentation is characterized 
by the presences of vesicles on the snout or coronary band, causing transient lameness, anorexia, 
and fever.  Vesicular lesions associated with SVA are clinically indistinguishable from those seen 
in foot-and-mouse disease, vesicular stomatitis, swine vesicular disease, and vesicular exanthema 
of swine (8, 11, 12). A final etiological diagnosis is required to distinguish SVA from other 
vesicular disease.  
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SVA has a genome length of approximately 7.3kb, which encodes three polyproteins, 
named polyprotein 1 to 3 (P1, P2, P3). The P1 region is both pre- and post-translationally cleaved 
into structural proteins: viral protein 1-4 (VP1-4) (3). Sixty copies of each viral protein make up 
an icosahedral capsid, with VP1-3 interlocking on the surface and VP4 found on the interior. While 
the pathogenic role of VP1 is unknown in SVA, it has proven highly immunogenic in SVA and 
other viruses of the Picornaviridae family (13, 14). The VP1 protein is also highly specific to each 
Picornavirus, with low sequence similarity between species. It is highly conserved within the 
species, with different strains showing 99-100% nucleotide identity and 100% amino acid identity 
(15). Crystallography has shown that SVA VP1 has multiple exposed loops that may be 
responsible for cell tropism and binding, including the BC loop, loop II, and FMDV loop. Unlike 
other picornaviruses, the hydrophobic pocket formed by the capsid proteins of SVA possess an 
entrance without a pocket factor that is nearly sealed. Due to the pocket structure, receptors and 
host cell binding does not mimic that described for other members of Picornaviridae (16). While 
recent studies have revealed affinity of the ANTXR1 cell receptor, commonly upregulated in 
tumor cells (17-20), no work has been completed with swine samples and information regarding 
the immunodominant regions of VP1 is not yet available. Additional knowledge on the antigenic 
regions of the VP1 protein would allow for better understanding of SVA pathogenesis and 
immunodiagnostics. 
In this study, SVA polyclonal antibodies and monoclonal antibodies of the SVA VP1 
protein were produced and characterized to map antigenic epitopes on the VP1 protein. These 
epitopes were further evaluated by SVA antisera from experimentally infected mice and swine 
samples collected from a clinical outbreak.  
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Materials and Methods 
Viruses and cells 
A SVA strain was isolated from grower-finisher pigs with vesicular lesions confirmed SVA 
positive by PCR at the Iowa State University Veterinary Diagnostic Laboratory. A NCI-H1299 
cell line (ATCC® CRL-5803) was maintained in RPMI 1640 (Gibco®, Carlsbad, CA, USA) at 
37°C and 5% CO2. Media was supplemented with 10% heat-inactivated fetal bovine serum (FBS, 
ATCC), 1% antibiotic-antimycotic (Gibco®) and 0.1% gentamicin (Gibco®). 
Generation of SVA-VP1 monoclonal and SVA polyclonal antibodies 
Polyclonal antibodies (pAbs) were generated by intraperitoneal inoculation of mice with 
inactivated SVA whole virus. A total of 10mL of 1x106 TCID50/mL of passage one SVA was 
treated with 5% formalin and ultracentrifugated for two hours at 35,000 rpm. The viral pellet was 
resuspended in 400 µL of phosphate buffered saline (PBS) and an aliquot of 50 μL was mixed with 
incomplete Freund's adjuvant at 1:1 volume ratio. Three six-week-old BALB/C mice were 
inoculated intraperitoneally, followed by a booster injection two weeks after primary inoculation. 
Beginning two weeks after the booster inoculation, blood was harvested and presence of SVA 
antibodies evaluated weekly by SVA-rVP1 ELISA. When SVA-rVP1 antibody titer reached a 
maximum concentration, mice were treated intraperitoneally with Pristane (Sigma-Aldrich, St. 
Louis, MO) and three days later given an intraperitoneal injection of SP2/O cells (approximately 
5 to 8 x 106 cells) to produce polyclonal ascites fluid. After 10 days, all mice were euthanized. 
Ascites fluid was collected and stored -20ºC. 
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Monoclonal antibodies (mAbs) against the recombinant SVA-VP1 (SVA-rVP1) protein 
were generated by GenScript (Piscataway, NJ, USA). Five six-week-old BALB/c mice were 
injected subcutaneously with 0.1 mg of SVA-rVP1 protein using MonoExpress immunization 
technique, twice at two-week intervals. Spleen cells were gathered and fused with SP2/0 myeloma 
cells. Hybridoma supernatants of parental clones were suspended in Dulbecco’s Modified Eagle’s 
Medium (DMEM) with 10% FBS, 1x HT supplement, 1x penicillin streptomycin, and 0.02% 
Sodium Azide. A total of 20 hybridomas were screened using indirect SVA-rVP1 ELISA and three 
hybridomas were selected for mAb production and purification: 4D10, 8F12, 10C2.  
The concentration of all SVA VP1-mAbs was normalized to 0.092 mg/mL for all ELISA 
testing. Isotyping was completed for using a rapid mouse immunoglobulin ELISA (Antagen 
Pharmaceuticals Inc, Boston, MA, USA) following vendor protocol. Briefly, each SVA VP1-mAb 
was diluted to 2 µg/mL and 100 µL was added to each cassette sample well and incubated for five 
minutes at room temperature. Antibody isotyping was read by red colorimetric changes in the 
specific site for each antibody class and subclass. 
Indirect rVP1-ELISA and SVA-whole virus ELISA 
A recombinant VP1 protein was generated in an Escherichia coli expression system. A 
codon-optimized version of the VP1 gene, 1,359 nt in size (Genbank #DQ641257) was synthesized 
in vitro (Sanghai Genery Biotech Co. Ltd, Shanghai, China) and amplified using a forward primer 
(5’- CAT CAT CAT CAT CAT CAT ATG TCT ACA GAT AAT GCA GAA ACG- 3’) and 
reverse primer (5’- AGA CTG CAG GTC GAC AAG CTT TTA ACC TGA CTG CAT CAG CAT 
C-3’). This PCR product was cloned into pCold II expression plasmid using the NovoRec © PCR 
One Step Directed Cloning Kit (Novoprotein Scientific Inc, Shanghai, China) and confirmed 
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through sequencing (Genewiz Inc, Suzhou, China) before being transformed into E. coli BL21 
(DE3) pLysD (Rosetta cells; InvitrogenTM, Carlsbad, CA, USA). This bacterial clone was grown 
in Luria-Bertani (LB) medium (InvitrogenTM) with 100µg/mL ampicillin and shaking 250 rpm at 
16 °C. After sixteen hours, cells were chilled to 4 °C and harvested by centrifugation at 3,500g for 
fifteen minutes. Cells were then resuspended in 20mM PBS, 500mM NaCl pH 7.4 and lysed by 
ultrasonication. The extracts were centrifuged at 50,000g for thirty minutes at 4 °C and fractions 
analyzed by 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The 
VP1 protein at 30.9 kDa was expressed as an inclusion body in the precipitate, and solubilized 
using a denaturing buffer including 20mM Tris, 6M Guanidine-HCl, 10mM β-Mercaptoethanol 
pH 8.0. The rVP1 protein was refolded in vitro to the native conformation and concentrated by 
dialysis with a refolding buffer consisting of 50mM Tris, 240mM NaCl, 10mM KCl, 2mM MgCl2, 
0.4M sucrose, 0.5M arginine, 0.05% Triton X-100, and dithiothreitol pH 8.2. The 278 amino acid 
sequence identity was confirmed.  
The rVP1 protein was utilized in ELISA testing as described by Gimenez et al. (2016). 
Ninety-six well high binding microtiter plates (Maxisorp, Nunc, Thermo Fisher Scientific, 
Agawam, MA, USA) were coated with 100µL of rVP1 at 0.18 µg/mL/well in a carbonate buffer, 
pH 8.2. Plates were incubated sixteen hours at 4 °C, then washed five times with phosphate 
buffered saline (PBS), pH 7.4, containing 0.1% Tween 20 (PBST) and blocked with a 1% 
weight/volume bovine serum albumin solution (Jackson ImmunoResearch Inc., West Grove, PA, 
USA) for two hours at 25 °C. Plates were dried at 37 °C for three hours and stored at 4 °C in a 
sealed bag with desiccant packets.  
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One-hundred µL of sample was added per well and incubated at 37°C for one hour. 
Samples were run in triplicate with a positive and negative control. Mouse serum, including mAbs 
and pAbs, was diluted in a newborn calf serum-based diluent at 1:50. Swine serum was diluted in 
a fish serum based diluent at 1:50. Plates were washed five times with PBST and then incubated 
with 100 µL of horseradish peroxidase-conjugated goat anti-mouse IgG Fc antibody (Pierce 
Protein Biology) diluted 1:5,000. Alternatively, for swine serum, goat anti-swine IgG Fc HRP 
conjugated antibody (Bethyl Laboratories, Montgomery, TX) was used at a 1:30,000 dilution. 
Peroxidase activity was monitored by adding 100 µL of tetramethylbenzidine-hydrogen peroxide 
(TMB) substrate (Surmodics, Eden Prairie, MN, USA) for 5 minutes at room temperature in a 
darkened environment. The reaction was terminated by addition of 100 µL of Nova-stop 
(Surmodics). Finally, optical density was measured at 450nm using an automatic plate reader 
(BioTek ELx800, Biotek ® Winooski, Vermont) operated with a commercial software (GEN5TM, 
Biotek ®). 
For SVA whole virus ELISA, virus was harvested by three cycles of freezing and thawing 
of the NCI-H1299 cell line (ATCC® CRL-5803) cells previously infected with SVA, recovered 
from a clinical case of vesicular disease. Cell culture supernatant was centrifuged for 15 minutes 
at 4,000 rpm and 4°Csupernatant was then spun for two hours 28,000 rpm and 4°C, and the 
resulting pellet was resuspended in PBS. One-hundred µL of viral particles were diluted 1:400 in 
PBS and coated onto 96-well high binding microtiter plates (Thermo Fisher Scientific). Whole 
virus ELISA plates were incubated for 16 hours at 4°C. Plates were washed five times with PBST 
and blocked with 1% bovine serum albumin solution (Jackson ImmunoResearch Inc.) for two 
hours at 25°C. Samples were diluted 1:50 and a total 100 µL per well were then incubated for one 
hour at 37°C followed by five washes with PBST. Reaction was revealed by adding 1:10,000 
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dilution of peroxidase conjugated goat anti-mouse IgG (Fc) antibody (Pierce Protein Biology) for 
30 minutes at 37°C. Addition of 100 µL per well of TMB allowed for visualization of the 
peroxidase reaction. Reactions were stopped with 100uL Nova-stop after 5 minutes. Optical 
density was read at 450 nm. 
VP1 peptide synthesis and indirect VP1 peptide ELISA 
Eighteen overlapping 20-mer peptides shifted by five amino acids, spanning the complete 
SVA-VP1 amino acid sequence, were synthesized (Novoprotein Scientific INC., Summit, NJ) and 
conjugated to keyhole limpet hemocyanin (KLH) at the N-terminus and hydroxyl at the C-terminus 
(Table 1). Reactivity of synthetic peptides was measured by two SVA-pAbs and three VP1-mAbs. 
Each peptide was thawed and diluted in phosphate buffered saline (PBS) (Life Technologies, CA) 
to a concentration of 1 µg/mL. One-hundred µL was added to high binding plate (Thermo 
Scientific, MA) and incubated sixteen hours at 4°C. After incubation, plates were washed five 
times with PBST using an automated plate washer (BioTek,Winooski, VT). Plates were blocked 
with 300 µL of bovine serum albumin (BSA) for two hours at room temperature (RT) and dried 
for 4 h at 37°C.  
SVA pAbs were diluted in newborn calf serum-based diluent via two-fold dilution from 
1:50 to 1:6400. One-hundred µL of two-fold serial dilutions of SVA pAbs, or 1:10 dilution of 
rVP1 mAbs were incubated in 96 well plates. One-hundred µL of goat anti-mouse IgG Fc 
conjugated with horseradish peroxidase (HRP) (Pierce Protein Biology) at 1:10,000 was incubated 
for 1 h at 37°C followed by five washes with 1 x PBS. One-hundred µL of tetramethylbenzidine-
hydrogen peroxide substrate (Surmodics) was incubated for 10 min at RT, and enzyme-substrate 
reaction was stopped with 100 µL Nova-stop (Surmodics). The reaction was quantified by 
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detection of absorbance at 450nm on an automated plate reader (BioTek). As negative control of 
100 µL of pre-immunization mouse serum at 1:100 dilution was incubated with each peptide. 
Antibody affinity against SVA-rVP1 in blocking ELISA  
 Antibody affinity selection of SVA pAb, mAb, and swine clinical samples were evaluated 
by SVA-rVP1 blocking ELISA. SVA pAb, mAb, and pre-immunization mouse serum were diluted 
in newborn calf-serum diluent. SVA-rVP1 protein was diluted to a concentration of 0.1, 1, 10, 25, 
50, and 100 µg/mL. SVA-rVP1 was added to serum in a 1:1 volume ratio and incubated for one 
hour at 37°C, then loaded into high-binding plates coated in SVA-rVP1 protein as described for 
SVA-rVP1 indirect ELISA. After one hour at 37°C, plates were washed and goat anti-mouse IgG 
(Fc) HRP (Pierce Biology) was added for one hour at 37°C. Plates were again washed and TMB 
was added for five minutes before stopping the reaction and reading optical density at 450 nm. 
This procedure was repeated using serum from five sows testing positive onSVA-rVP1 ELISA in 
a 2015 clinical outbreak (4). Samples and SVA-rVP1 were diluted in a fish serum diluent. A goat 
anti-swine IgG Fc HRP (Bethyl Laboratories, Montgomery, TX, USA) conjugate was used. Serum 
from five specific pathogen free pigs were run as negative controls.  
SVA Peptide Blocking ELISA 
SVA VP1 peptide affinity was also evaluated by SVA peptide blocking ELISA. Each of 
the eighteen peptides was diluted in distilled deionized water to a concentration of 0.2, 2, 20, 50, 
100, and 200 µg/mL. An equal volume of mAb 4D10 at 5.75 x 10-5 µg/µL was added to each 
sample and incubated at 37°C for one hour with shaking. Sample was loaded into SVA-rVP1 
coated plates for one hour at 37°C. After washing five times with PBST, goat anti-mouse IgG Fc 
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HRP (Pierce Biology) was added for one hour at 37°C. Plates were washed again and substrate 
added. After stopping the enzyme-substrate reaction, plates were read at 450nm. Blocking ELISA 
was repeated with pAb 769L. A blocking SVA-rVP1 ELISA was run using serum collected from 
five sows testing SVA-rVP1 ELISA positive in a 2015 clinical outbreak (4). Samples were diluted 
1:50 in a fish serum-based diluent, then incubated for one hour at 37°C with an equal volume of 
each peptide diluted in a fish serum diluent to 0.2, 2, 20, 50, 100, and 200 µg/mL. The conjugate 
used for these samples was goat anti-swine IgG Fc HRP (Bethyl Laboratories, Montgomery, TX, 
USA) conjugate. Serum from five specific pathogen free pigs were run as negative controls.  
Western Blot 
Reactivity of both SVA pAbs and rVP1 mAbs against whole virus particles was evaluated 
in six serial dilutions of a 1x106TCID50/mL SVA. Reactivity against SVA-rVP1 was evaluated 
against both antibodies in six different dilutions of SVA-rVP1. Both SVA particles and rVP1 were 
mixed in Laemmli loading buffer (Bio-Rad, Hercules, CA, USA) with 5% 2-mercaptoethanol 
(Sigma Aldrich), denatured for five minutes at 100°C and loaded into an 8-16% Tris Glycine gel 
(Bio-Rad). Proteins were transferred to nitrocellulose membranes (Bio-Rad) utilizing the mini 
protean transfer system from Bio-Rad using TGX buffer with 20% methanol. The membranes were 
then blocked for 1 hour at room temperature with Licor blocking buffer containing 0.01% Tween-
20 (LBT) and washed twice with PBST. SVA pAbs and SVA-rVP1 mAbs were diluted in LBT at 
1:10,000 and 1:500 respectively and incubated for one hour at room temperature. The membranes 
were washed four times with PBST prior to incubation with Alexa Fluor 790 goat anti-mouse IgG 
H+L (InvitrogenTM, Carlsbad, CA, USA) at 1:5,000 in LBT for one hour at room temperature. 
Blots were read using an Odyssey Infrared Imaging System (LICOR Biosciences, Lincoln, NE).  
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Indirect immunofluorescence assay (IFA) 
NCI-H1299 cells were grown in 96-well plates. Each well was inoculated with 1x103 
TCID50/mL SVA. After 24 hours, cells were fixed with 200 µL cold 90% acetone for 10 minutes 
at 4°C. Cells were washed with 200 µL PBS, then incubated with 50 µL two-fold serial dilution 
mouse serum at 37°C for one hour. Wells were washed three times with 200 µL PBS and incubated 
with 50 µL of FITC labeled anti-mouse IgG (KPL Scientific, Montreal, Quebec, CAN), diluted 
1:100, at 37°C for 30 minutes. Plates were washed three times with PBS and examined under a 
fluorescence microscope. 
Virus Neutralization Assay (VN) 
Virus neutralization assay was performed using serum samples that were previously heat 
inactivated at 56°C for 30 minutes. mAb and pAb were not heat inactivated. The sera were two-
fold serially diluted (1:20 to 1:40,960) in RPMI 1640 (25 µl/well) in 96-well plate. An equal 
volume of 1x102 TCID50/mL SVA was added to the mouse sera. The plate was incubated for one 
hour at 37°C, then the 50 µl serum-virus mixture was inoculated into NCI-H1299 cells in a 96-
well plate. The plate was incubated at 37°C for 24 hours and then fixed with 90% acetone. The 
infection of the cells was checked by SVA IFA described above. The virus neutralization titer was 
determined as the highest serum dilution where IFA was negative. Each VN assay was performed 
in duplicate. 
Fluorescent Focus Neutralization (FFN)   
NCI-H1299 cells (ATCC CRL-5803) were cultured in 96 well flat bottom black tissue 
culture treated microplates (Corning) in RPMI-1640 media containing 1% Penicillin-Streptomycin 
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and 5% FBS at 37°C and 5% CO2 for 24 hours. Serum samples were heat inactivated for 30 
minutes at 56°C. Monoclonal and polyclonal antibodies were not heat inactivated. In a dilution 
plate, a two-fold dilution from 1:20 to 1:40,960 was completed for all samples and controls. SVA 
stock was diluted to TCID50 of 10,000 in RMPI. One-hundred µL of virus was added to 100 µL 
diluted sample and incubated at 37°C for one hour. Next, the virus-sample combination was added 
to cells, and incubated 1.5 hours at 37°C and 5% CO2. The test plate was washed, then inoculation 
media added for 24 hours at 37°C and 5% CO2. Media was then removed, and cells fixed with 50 
µL of 80% acetone for 15 minutes at room temperature. After removing acetone, plates were dried 
for 30 minutes. SVA VP1 monoclonal antibody was diluted 1:200 in PBS with 0.1% BSA, and 50 
µL added per well for 1 hour at 37°C. Plates were washed three times with PBS with 0.1% BSA, 
then 50 µL of FITC-labeled goat anti-mouse IgG (KPL Scientific) was added for 45 minutes at 
37°C. Plates were washed and PBS added to each well. Finally, plates were read using a Spectra 
Max i3x cytometer using SoftMax Pro software (6.5) at 456 nm excitation and 541 nm emission, 
reading one site per well. 
Statistical Analysis 
All experiments were performed in duplicate or triplicate technical replicates and analyzed 
using GraphPad Prism Version 6. Mean and standard deviation were charted. In characterizing 
generated antibodies, a two-way ANOVA with Tukey corrections made post-test for multiple 
comparisons was used to determine significance of results in comparison to a negative control. An 
unpaired t-test with no correction for multiple comparisons was used to evaluate results between 
ELISA tests for each antibody. An alpha level of 0.05 was used for all analyses. A two-tailed, 
nonparametric t-test was used for analysis of IFA and VN. The epitope ELISA was analyzed using 
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an unpaired t-test with no corrections for multiple comparisons. For blocking ELISAs, inhibitory 
concentration (IC50) was used. A curve was generated using degradation of positive controls.  
Results 
SVA-rVP1 mAbs generated in vitro do not recognized whole virus particles  
Binding activity of two SVA pAbs generated against the whole virus particle and three 
mAbs generated against a recombinant VP1 protein were evaluated by a whole virus ELISA, SVA-
rVP1 ELISA, and western blot. No significant difference in binding activity against rVP1 protein 
was observed amongst SVA mAbs or SVA pAbs in a SVA-rVP1 ELISA (Figure 1). Both SVA 
pAbs showed significant binding activity against SVA viral particles in a WV ELISA; however, 
none of the SVA mAbs showed significant reactivity compared with negative controls (Figure 1).   
The binding activity of SVA pAbs and mAbs against SVA WV particles and SVA-
rVP1protein was further confirmed by western blot. Serial dilution of detergent treated virus 
(molecular weight 65 kDa) and serial dilutions of SVA rVP1 protein (molecular weight 31 kDa) 
were incubated with two SVA pAbs.  SVA pAbs binding activity against SVA WV particles was 
detectable to a minimum of concentration of 104 virus particles (Figure 2A) and a minimum 
concentration of 50 ng of SVA rVP1 protein (Figure 2B). All mAbs showed strong reactivity 
against SVA rVP1 protein (Figure 2C); however, no reactivity was observed against SVA WV 
particles (figure not shown). 
SVA VP1 mAbs and SVA pAbs can detect virus replication by immunofluorescence assay  
An indirect immunofluorescence assay showed that both SVA-rVP1 mAb and pAb were 
able to detect SVA infection in NCI-H1299 cells.  No significant difference in IFA titers between 
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SVA mAb and pAb was observed (Figure 3A). Both antibodies showed strong cytoplasmic 
fluorescent signal (Figure 3B).  
SVA pAbs but not SVA-rVP1 mAbs present neutralizing activity in vitro 
Viral neutralizing activity of SVA pAb and SVA rVP1-mAb was evaluated in vitro. Serial 
dilutions of SVA pAb 769L and SVA mAb 4D10 were incubated with SVA and neutralizing 
activity was evaluated by IFA. SVA pAb showed neutralizing activity to a 1:2,560 dilution, while 
no neutralizing activity was observed with mAb (Figure 4). In addition, five clinical swine samples 
positive by SVA-rVP1 ELISA showed strong neutralization titers varying from 1:80 to 1:2,560 
(data not shown). No detectable neutralizing activity was observed in five specific pathogen free 
pig samples used as negative controls. 
SVA mAb but not SVA pAb show differential binding activity against SVA-VP1 epitopes 
by indirect ELISA epitope mapping  
To localize linear B-cell epitopes of SVA VP1 involved in immunogenicity, the binding 
activity of SVA pAb and mAb was evaluated against sequential, overlapping peptides of the SVA-
rVP1 protein by indirect peptide ELISA. SVA pAb showed significant reactivity against all 
peptides spanning the entire SVA VP1 protein compared to a negative control. In addition, no 
significant differences in intensity were observed among peptides by SVA pAb detection (Figure 
5A). However, SVA mAb was capable of detecting significantly higher signal from only four non-
overlapping amino acid residues spanning amino acids 1-20, 45-140, 150-170, and 180-230. The 
peptide spanning amino acid 1-20 showed a particularly high and significant reactivity compared 
to the peptides spanning amino acids 45-140, 150-170, and 180-230 (Figure 5B).  
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In order to rule out potential cross reactivity between the SVA VP1 peptides used in this 
study and other members of the family Picornaviridae, a phylogenetic analysis using a NCBI 
BLAST (version 2.5.0) was performed. No sequence homologies were seen between other 
members of the Picornavirus family and the eighteen SVA rVP1 peptides. 
A group of SVA VP1 linear epitopes shows a differential inhibitory effect on SVA mAb but 
not in SVA pAbs against rVP1 protein  
Specific peptide inhibitory activity on SVA pAb and SVA mAb against SVA rVP1 protein 
was evaluated by blocking ELISA. Ten log dilution concentrations of each peptide were incubated 
for 1 hour either with SVA pAb or mAb. Then, inhibitory binding concentration 50 (IC50) against 
SVA rVP1 protein was evaluated by SVA rVP1 ELISA.  As a positive control, inhibitory activity 
of the whole rVP1 protein was also evaluated. Pre-incubation of rVP1 protein with SVA mAbs 
resulted in significant binding inhibition in a dose-dependent manner, while SVA pAbs showed a 
minimal reduction in binding activity against rVP1 protein. When SVA pAb binding activity 
against rVP1 was evaluated after individual peptide blockage, all epitopes showed partial binding 
inhibitory effect. However, none of the peptides demonstrated a 50% or greater inhibitory effect 
on SVA pAb binding activity to SVA rVP1 protein (Figure 6A). All eighteen peptides also 
possessed some ability to block binding activity of SVA mAb to SVA-rVP1. However, four 
peptides spanning amino acids 1-20, 60-80, 105-125, and 120-140 of SVA-rVP1 showed potent 
inhibition, reducing SVA mAb binding activity to rVP1 protein by more than 50% (Figure 6B). 
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Anatomic location of reactive epitopes in SVA-rVP1 protein 
Peptide interaction and availability was predicted using SWISS MODEL (Figure 7). 
Peptide 1, spanning the first twenty amino acids of the VP1 protein, had high substrate availability 
as was highly exposed in the individual protein.  
Discussion 
The VP1 protein of SVA is a structural protein that has been used in diagnostic testing, for 
ELISA and PCR (21, 22), due to its highly conserved sequence, immunogenicity, and virus 
specificity. While the other capsid proteins are highly conserved among picornaviruses, VP1 is 
unique to the Senecavirus genera and involved in cell tropism (2). This study aims to examine the 
role of linear epitopes of the VP1 protein in the SVA humoral immune response.  
SVA pAb and SVA rVP1 mAb characterization showed that SVA rVP1-mAb did not react 
against a whole virus on both ELISA and western blot. It is possible that conformational epitopes 
are responsible for this interaction. Therefore, differences in folding and interaction among 
conformational epitopes in whole virus particles may mask specific binding sites needed for SVA 
VP1 mAb antigen interaction. In addition, this lack of reactivity against whole virus particles could 
be due to differences in antibody affinity due structural differences in protein folding of the rVP1 
compared with proteins naturally expressed during viral replication in live cells (23). SVA VP1 is 
part of a polyprotein, and interaction with other areas of the polyprotein may be vital for viral 
infection and replication. In foot and mouth disease virus, the GH loop demonstrates flexibility 
and an ability fold in different configurations (24). The hydrophobic pocket of VP1 has been shown 
in other picornaviruses to be related to capsid stability and genome release. This could be a 
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contributing aspect to the immunogenicity observed for SVA VP1. The pocket is located under a 
canyon in the protein structure and its entrance is almost entirely sealed by other residues of VP1 
(2, 25). In other viruses, mAb for VP1 has been shown to bind deep in the canyon and have more 
than one region of receptor binding (26). The SVA-rVP1 could possess differences in this 
structural pocket, due to folding changes, that prevent natural epitopes from being exposed. Thus, 
a combination of these VP1 protein structural features could contribute to the difference in SVA 
mAbs binding activity to whole virus particles. 
Although SVA rVP1-mAbs were not capable of detecting WV particles by WV ELISA 
and western blot, both SVA pAb and mAb recognized SVA replication through 
immunofluorescence staining, with virus localized mainly in the cell cytoplasm. This difference 
may be explained by the biological virus-cell interaction allowing exposure of natural epitopes 
during viral replication. Whole virus ELISA and western blot depend on virus interaction with the 
plate or viral degradation through detergent treatment to allow conformational changes in regions 
necessary for antibody-antigen interaction (27, 28). SVA and other picornaviruses have internal 
ribosomal entry sights and other antigenic regions that must be post-translationally modified by 
cellular proteases to reach an active configuration (29). Without cellular interaction, proteins 
expressed in the virus particles are not post-translationally modified and would not express the full 
repertoire of specific, active binding sites necessary for antibodies generated against VP1 protein.  
Antibody generated against whole viral particles demonstrated an ability to neutralize 
SVA, while no neutralizing activity was observed with SVA rVP1-mAbs. All monoclonal 
antibodies evaluated in this study were IgG isotype. Previous experiments in swine demonstrated 
that neutralizing activity is likely related to the presence of IgM (30). In addition, the same study 
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also showed an earlier and higher neutralizing activity against VP2 compared with VP1 antibodies. 
In this study, serum collected from clinically affected sows showed also neutralizing activity, 
which might suggest that that VP1 is not sufficient to generate antibody protection, and interaction 
with multiple structural proteins expressed during SVA replication might be necessary. 
The SVA VP1 epitope, spanning amino acids 1-20 of the SVA-rVP1 protein, showed a 
high reactivity and was capable of inhibiting interaction between SVA mAb and SVA rVP1. These 
results suggest that this linear region of SVA-VP1 plays an important role in the humoral immune 
response. A SWISS-MODEL of the VP1 protein showed that this region, residues 1-20, is highly 
exposed when the protein is examined alone. This vulnerable position may contribute to the ability 
of this amino acid region to induce or be part of induction of an IgG response. However, the spatial 
interaction of this amino acid region, as well as the whole VP1 protein with the remaining capsid 
proteins, must be considered to better understand the exposure and interactions of this epitope. 
While other peptides showed variable binding activity and inhibitory effects on SVA mAb 
interaction with rVP1 protein, peptides spanning amino acid 60-80, 105-125, and 120-140 were 
capable of significantly inhibiting mAb binding activity to SVA-rVP1. These regions may act as 
additional linear epitopes capable of inducing a humoral immune response. The twenty amino acid 
segments generated in this study were all recognized by SVA pAb, but could not alone interfere 
with its interaction with the viral protein. None of the peptides evaluated were able to significantly 
reduce binding activity of SVA pAb or swine serum against rVP1 protein. It should be noted that 
the swine serum was collected from sows during a clinical outbreak, while mouse serum was 
collected from experimentally inoculated animals boostered with a specific, known dose of virus 
at specific time intervals. Thus, differences observed in clinical samples could be associated with 
100 
 
time and dose of exposure. From both, it can be concluded that epitopes of rVP1 alone cannot 
induce antibody inhibitory effect in SVA pAb generated during experimental or natural infection. 
Other protein interactions are necessary to drive an inhibitory humoral response (23). 
Recent studies have shown that SVA interacts with cells through the anthrax toxin receptor 
1 (ANTXR1), also known as tumor endothelial marker-8 (TEM8). This receptor is upregulated on 
tumor cells, which may explain the success of SVA as an oncolytic agent in vitro. While no work 
has been done in vivo or with swine cells, SVA has shown a high affinity for this receptor and 
some regions of the capsid proteins have been identified as putative areas of interaction with 
ANTXR1. Cryo-electron microscopy single-particle analysis showed ANTXR1 amino acid 
interaction with the BC loop (residues 48-72), loop II (92-107), and FMDV loop (183-213) of 
VP1, as well as the puff of VP2 (170-198) and the knob of VP3 (55-71). Additionally the BC loop 
and loop II formed hydrogen bonds with the receptor (19). Inhibitory activity of SVA mAb against 
rVP1 induced by epitopes spanning amino acid residues 60-80 and 105-125 might reflect the 
binding effect observed by ANTXR1 to BC loop (residues 48-72) and loop II (residues 92-107). 
It is important to note that the BC loop and loop II of VP1 interact with the puff of VP2 to form 
the maximum capsid diameter, 325 Å, at the five-fold axis of the capsid (2). This elevated exposure 
may contribute to reactivity with host cells. Additionally, binding resulted in minor changes in 
capsid conformation (19), indicating that models and bioinformatics can give only a limited 
amount of information.  
Zhao et al. utilized bioinformatics to predict antigenic epitopes of the VP1 protein to 
evaluate SVA evolution. Their analyses predicted multiple B and T cell epitopes on the VP1 
protein. Of the nine predicted B cell epitopes, residues 1-6, 14-18, 57-63, and 144-148 were 
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included. These regions align with three of the areas identified in our swine and mouse-based 
mapping study. Software also predicted that secondary structures were of high importance for 
immune recognition (31). These regions may be involved in conformational epitopes. 
This study focused on the role of VP1 protein in the host humoral immune response, 
particularly IgG. It is important to acknowledge to role of IgM, which has been shown to be highly 
mediated by the VP2 and VP3 proteins. Additionally, while the humoral response is required to 
control picornavirus infection through limiting viremia, tissue spread, and severity, the cellular 
immune response also plays a role in virus defense. Flow cytometry studies showed that the 
external capsid is essential for CD4+ T cell response and early neutralizing antibody production 
(30). More information is necessary to determine if this set of linear epitopes with inhibitory 
activity within VP1 protein can act as decoy epitopes, delaying antibody neutralizing activity 
against SVA. Assessment of these linear regions forming conformational epitopes may provide 
further information regarding their potential role in the humoral response during SVA infection. 
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Figure Legends 
 
Figure 1- SVA pAbs and mAbs characterization by SVA WV and SVA-rVP1 ELISA. 
Reactivity against SVA recombinant VP1 protein was seen between both pAbs and all three mAbs 
on SVA-rVP1 ELISA when compared to a pre-injection negative control. Significant reactivity 
against SVA WV particles on WV ELISA was only with SVA pAbs and no significant reactivity 
was observed with any of the SVA rVP1-mAbs. Values represent mean and SD of three technical 
replicates. After completion of ELISA characterization, pAb 769L and mAb 4D10 were selected 
to be representative of the generated antibodies. 
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 Figure 2- Characterization of SVA pAbs and mAbs by western blot. Western blot was 
completed using a titrated concentration of detergent treated SVA WV particles and SVA VP1 
recombinant protein. SVA pAb 769L showed reactivity against WV particles (2A) and producing 
one band correlating to the molecular weight of SVA-VP1 (2B). SVA mAbs showed binding 
activity against the SAV-rVP1 (2C), but not SVA WV particles (figure not shown).  
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Figure 3- SVA pAbs and mAbs viral replication detection by IFA. SVA replication in NCI-
H1299 cells was evaluated by IFA with SVA pAbs and mAbs. Both antibodies were capable of 
specifically detecting SVA replication after 24 hpi. No significant difference in viral detection was 
observed between SVA pAb 769L and SVA mAb 4D10 (3A). Both antibodies demonstrated a 
high intracytoplasmic viral replication detection (3B). Values represent mean and SD of three 
technical replicates.  
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Figure 4- SVA pAb and SVA rVP1 mAb neutralizing activity detected by IFA. Significant 
differences were observed between viral neutralizing activity of SVA pAb and SVA rVP1-mAb. 
Both mAb 4D10 and pre-immunized serum negative control did not showed neutralizing activity 
against SVA, while SVA pAb was capable of neutralizing virus. Values represent mean and SD 
of three technical replicates. 
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Figure 5- SVA VP1 epitope mapping evaluated by indirect epitope ELISA. SVA-VP1 epitopes 
were developed and utilized in indirect ELISA. pAb showed reactivity against all eighteen epitopes 
(5A). High reactivity was seen with mAb against peptides 1-20 of VP1 on indirect ELISA (5B). 
Values represent OD means and SE of three technical replicates. 
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Figure 6 - SVA VP1 epitopes inhibitory effect on SVA mAb and SVA pAb binding activity 
to rVP1 protein by blocking ELISA. All epitopes showed a partial inhibitory effect on binding; 
however, none of peptides demonstrated a 50% or greater inhibition effect on SVA pAb binding 
activity to SVA protein (6A). All eighteen peptides also possessed some ability to block binding 
activity of SVA mAb with SVA-rVP1 (7B). However, four peptides spanning amino acids 1-20, 
60-80, 105-125, and 120-140 of SVA-rVP1 showed potent inhibition, with SVA mAb to rVP1 
protein reduced by more than 50% (6 B, C). 
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Figure 7- SWISS MODEL was used to generate a model of SVA-rVP1. 
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Tables 
Table 1: VP1 epitope regions. Eighteen peptides spanning the length of SVA-rVP1 were 
generated. Peptides were 20 amino acids and length and overlapping by five peptides. Peptide 
purity was at 85% and all peptides except SVA-VP1-PEP5, 8, and 17 were optimized through 
addition of cysteine.    
Name of peptide  Sequence of peptide Position of amino acid  Length (aa) 
SVA-VP1-PEP1 STDNAETGVIEAGNTDTDFS 1-20 20 
SVA-VP1-PEP 2 DTDFSGELAAPGSNHTNVKF 15-35 20 
SVA-VP1-PEP 3 TNVKFLFDRSRLLNVIKVLE 30-50 20 
SVA-VP1-PEP 4 IKVLEKDAVFPRPFPTQEGA 45-65 20 
SVA-VP1-PEP 5 TQEGAQQDDGYFCLLTPRPT 60-80 20 
SVA-VP1-PEP 6 TPRPTVASRPATRFGLYANP 75-95 20 
SVA-VP1-PEP 7 LYANPSGSGVLANTSLDFNF 90-110 20 
SVA-VP1-PEP 8 LDFNFYSLACFTYFRSDLEV 105-125 20 
SVA-VP1-PEP 9 SDLEVTVVSLEPDLEFAVGW 120-140 20 
SVA-VP1-PEP 10 FAVGWFPSGSEYQASSFVYD 135-155 20 
SVA-VP1-PEP 11 SFVYDQLHVPFHFTGRTPRA 150-170 20 
SVA-VP1-PEP 12 RTPRAFASKGGKVSFVLPWN 165-185 20 
SVA-VP1-PEP 13 VLPWNSVSSVLPVRWGGASK 180-200 20 
SVA-VP1-PEP 14 GGASKLSSATRGLPAHADWG 195-215 20 
SVA-VP1-PEP 15 HADWGTIYAFVPRPNEKKST 210-230 20 
SVA-VP1-PEP 16 EKKSTAVKHVAVYIRYKNAR 225-245 20 
SVA-VP1-PEP 17 YKNARAWCPSMLPFRSYKQK 240-260 20 
SVA-VP1-PEP 18 SYKQKMLMQ 255-264 9 
 
113 
 
CHAPTER 5: GENERAL CONCLUSION 
Summary 
 SVA is a single-strand, positive sense RNA virus in the family Picornaviridae that has 
recently been associated with outbreaks of vesicular disease and epidemic transient neonatal losses 
in swine. Such outbreaks have been described in multiple countries including the United States, 
Brazil, Canada, China, Vietnam, Colombia, and Thailand. Clinical signs of SVA infection have 
only been described in swine and cannot be from other vesicular diseases including FMDV, VES, 
VS, and SVD. Diagnosis is achieved through multiple direct and indirect methods including PCR, 
VN, ISH, ELISA, and IFA. After natural exposure, the virus produces viral shedding and a short 
viremia. Viral particles are detectable during a short viremia and in the feces of clinically affected 
animals, as well as those without clinical signs. Additionally, clinically healthy animals at the site 
out herd outbreaks have been shown to develop an IgG response, suggestive a subclinical 
presentation. More information is needed regarding the pathogenesis and transmission of SVA in 
order to develop sound protocols for biosecurity, vaccination, and procedures during outbreaks.  
 Serological studies show that the proportion of seropositive animals in SVA positive farms 
did not differ between clinically and non-clinically affected animals. However, there is not 
information available regarding the seroprevalence on United States’ farms without clinical IVD 
or ETNL associated with SVA. Here we determined the seroprevalence of SVA in commercial 
swine in the USA. A total of 2,433 sows and 3,654 grower/finisher serum samples were collected 
from farms with no history of IVD, ETNL, and SVA diagnosis during 2016 at ISU-VDL. Thirty 
animals were selected from each unique site n=219 (n=88 sows; n=131 grower-finishers) 
representing 18 USA states. Sera were tested using SVA-rVP1 ELISA and indirect 
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immunofluorescence assay (IFA). The overall seroprevalence detected by rVP1-ELISA was 
26.2% (CI ±1.76) and 8.7% (CI ±0.92), and by IFA was 15.9% (CI ±1.46) and 5.7% (CI ±0.75) 
for sows and grower-finishers, respectively. The between farm prevalence was 75.8% (CI ±8.8) 
and 42.7 % (CI ±8.5) for sow and grower-fisher herds. The within herd prevalence for sows had 
the following distribution: 58.2% of sites had 1-50% seropositive rates, 10.98% ranging from 51-
70%, and 18.68% between 71-100%. For grower-finisher premises, 70.8% of farmed fell into the 
1-50% seropositive range, 5.5% from 51-70%, and 1.8% in 71-100%. Clinically healthy sows and 
grower-finisher pigs possessed antibody against SVA with variable within herd prevalence. The 
presence of antibodies in grower-finishers indicates that animals are subclinically infected during 
the grower-finisher stage or lesions are going undetected. These results strongly suggest that SVA 
is circulating subclinically in United States’ swine population. 
Murine models have been described for the study of many members of the family 
Picornaviridae. Previous studies with foot and mouth disease virus have shown that mouse models 
can reproduce vesicular disease and mortality. However, these clinical outcomes appear to be 
dependent on mouse strain and age(1)(1)(1). In this study, five different mouse strains including 
BALB/C, C57BL/6, SJL/J, Swiss, and SCID showed detectable viral shedding during the 14 day 
study, in addition to viral detection in multiple tissues. All mouse strains, except for SCID mice, 
developed a strong humoral immune response by 14 dpi. Despite this strong evidence of viral 
replication and systemic spreading of the virus, we did not observed lethality or significant clinical 
signs of systemic illness. In addition, gross and histological evaluation showed that SVA does not 
induce cutaneous vesicles or significant lesions in other tissues at 14 dpi. Based on these results, 
we suggest that SVA can produce subclinical infection in multiple strains of laboratory mice by 
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subcutaneous inoculation. No clinical differences were observed among the different infectious 
routes in this study. IP and SC inoculation appeared to cause subclinical infection. In both groups 
there was acute viremia and viral shedding in feces detected within three dpi. Unlike pigs, fighting 
and grooming play a large role in the spread of viral disease in mice. Our results suggest that SC 
and IP route better mimic the natural exposures that would occur through biting, grooming, and 
physical contact than IN route. Swine appear to be the only natural host for SVA; however, 
retrospective studies demonstrated the presence of SVA neutralizing antibodies in mice and cattle. 
In the current study, we evaluated the presence and dynamic of the IgG antibody response in 
different infectious routes. The production of IgG antibody after SVA infection in mice is acute, 
with antibodies levels detectable after 7 dpi. This rapid development of specific humoral response 
is consistent with results observed in experimentally inoculated pigs. Mice may play a role in the 
transmission of SVA as a vector or reservoir for disease, allowing for virus to spread from one 
swine site to another through shedding in the feces or urine, or through direct contact. As wild 
mice as widespread across the United States and within production animal housing, viral 
transmission and movement of mice would allow SVA to spread over a wide geographic distance. 
Risk of SVA infection in mice may be decreased through increased pest management and 
biosecurity. 
The VP1 protein of SVA is a highly conserved and immunogenic structural protein. While 
the other capsid proteins are highly conserved among picornaviruses, VP1 is unique to the 
Senecavirus genera and involved in cell tropism. This study aims to examine the role of linear 
epitopes of the VP1 protein in the SVA humoral immune response. Immunogenic regions of the 
SVA-VP1 protein were examined through epitope mapping. The binding activity of SVA pAbs 
and mAbs were evaluated eighteen epitopes of the rVP1 protein. Epitopes were twenty amino acids 
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in length with a 5-mer overlap. While other peptides showed variable binding activity and 
inhibitory effects on SVA mAb interaction with rVP1 protein, peptides spanning amino acid 60-
80, 105-125, and 120-140 were capable of significantly inhibiting mAb binding activity to SVA-
rVP1. Additionally, the epitopes spanning aa 60-80 and 105-125 lie on the BC loop and loop II of 
the VP1 protein, respectively. Cryo-electron microscopy has shown that these regions interact with 
the ANTXR1 receptor in vitro. Our results suggest that a set of four linear epitopes of the VP1 
protein are responsible for IgG humoral response against VP1 during SVA infection.. Additional 
work is warranted to determine the role of these regions as in their conformational, native structure; 
their interaction with other immunogenic regions of the VP1 protein and other structural proteins; 
and their ability to induce a neutralizing antibody response. 
Conclusions 
 SVA appears to be circulating subclinically in healthy swine herds distributed across the 
United States, with seropositive animals detected in both breeding and grower/finisher herds. 
Laboratory mice undergo subclinical SVA infection and are capable of shedding viral particles in 
the feces. Wild mice could act as a source of transmission between swine herds as a reservoir host 
or vector. SVA VP1 protein plays a role in the humoral response of the host driven by a set of 
linear epitopes. However, these linear epitopes are not sufficient to confer protection and may need 
to be expressed in their native structure or interact with other immunogenic regions of the other 
structural proteins.  
 
 
